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1 Introduction 
 
The prostate form part of the accessory male sex glands and is widely conserved among all 
mammals. During ejaculation the prostate secrets a clear and slightly alkaline (pH 7,29) fluid 
in the urethra that is expulsed to the seminal fluid (Ross and Pawlina 2016; Hayward and 
Cunha 2000). Various studies investigated the chemical composition of the prostate secretory 
material. Prostate secretion mainly consists of immunoglobulins, prostaglandins, 
carbohydrates, citrate, polyamines, proteins, acid phosphatase and ions like Zinc (Costello and 
Franklin 2016; Bistulfi et al. 2016; Attiga et al. 2000). 
 
1.1   From gross anatomy to histology  
1.1.1   The rodent prostate 
The rodent prostate is divided into four different zones according to their location around the 
urethra, described as ventral, lateral, dorsal and anterior lobes (Fig.1) and invested in a thin 
membrane (Knoblaugh and True L. 2011). The prostate lobes do not entirely encircle the 
urethra and consist of epithelium-lined acini surrounded by stromal matrix. Loosely 
embedded, the collagenous extracellular matrix contains fibroblasts, blood vessels, wandering 
connective tissue cells, nerve terminals, lymphatics as well smooth muscle cells (SMC) that 
enclose each prostatic acinus (Jesik et al. 1982). 
 
The two ventral lobes of the rat prostate are attached to the ventral aspect of the urethra. A 
layer of connective tissue and a series of ducts lined with columnar epithelium drain into the 
urethra (Cunha et al. 1987). All (2-3) ducts are longitudinally folded with numerous closely 
packed layers of smooth muscle cells, alternating a longitudinal and circular arrangement and 
interspersed by small capillaries between the duct wall and the surrounding SMCs (Ichihara et 
al. 1978). Together both ventral lobes represent the largest part of the rat prostate that requires 
half of the entire prostate mass. Acini of the ventral lobes show typically a large degree of 
infolding. 
 
The lateral prostate is localized directly beneath the seminal vesicle, which is partially 
overlapping the ventral lobes and dorsally blended into the dorsal lobes. 5-7 ducts are 
connecting the lateral lobe with the urethra, surrounded by a thick stroma. Acini of the lateral 
prostate show a moderate epithelial infolding.  
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The dorsal prostate is found just behind the attachment of the seminal vesicle and 
inferioposterior to the bladder. 5-6 ducts are forming a complex and extensively arborized 
ductal network. Compared to other lobes epithelial infoldings are reduced (Hayashi et al. 
1991).  
 
The anterior lobes, also known as coagulating glands, are directly attached to the lesser 
curvature of the seminal vesicles. In contrast to the other lobes, the anterior prostate is more 
elongated and tubular with a papillary growth pattern. Its epithelium is cuboidal to columnar 
and filled with eosinophilic cytoplasm (Ittmann 2017). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1: Gross anatomy of the rat prostate.                                                                                                     
View in ventral and dorsal orientation. Modified from Prins and Lindgren 2015. 
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1.1.2   The human prostate 
Considered to be the largest accessory sex gland of the reproductive tract, the prostate is 
mostly described to equal a walnut in form and shape, although spherical and quadrangular 
forms could also be found. The human prostate encloses the prostatic part of the urethra 
completely, inferior to the bladder. The gland consists of four different zones: central, 
transition and peripheral zone, enclosed by the anterior fibromuscular stroma (Fig.2). 
Approximately 30 to 50 tubuloalveolar glands that enter 15 to 30 excretory ducts are 
embedded mainly in the furrows lateral to the colliculus seminalis. Each zone exhibits a 
typical histology and function.  
 
The cone-shaped central zone has its wider portion at the base of the prostate and contains 
around 25% of the prostate mass. This zone is found to be widely resistant to carcinoma and 
inflammation.  
70% of the prostate mass is concentrated in the peripheral zone that ranges from the lateral to 
the posterior part of the prostate and surrounds the central zone. The peripheral zone is the 
main site of origin for prostate carcinomas.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2: Gross anatomy of the human prostate.                                                                                             
View in sagittal orientation. Modified from Wein et al., 2011. 
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The transition zone occupies only 5% of the prostate tissue. Due to its close proximity to the 
urethra, the transition zone is capable to compress the urethra that causes painful bladder 
outlet obstructions, in case of benign prostatic hyperplasia (Ross and Pawlina 2016; Aumüller 
et al. 1979).  
 
Human prostatic glands and ducts are lined by three types of glandular epithelium: luminal, 
basal and neuroendocrine cells. The fibromuscular stroma consists of numerous smooth 
muscle cells, interspersed with fibroblasts, nerve fibers and blood vessels. In contrast to the 
thin fibromuscular stroma in the rodent prostate, the human prostatic stroma is much more 
distinctive (Ittmann 2017).  
    
1.2   Growing up: morphogenesis of the prostate 
Because development is a continual process and not a series of defined stages, it is difficult to 
determine the exact time point of certain developmental stages during puberty. However, 
puberty is usually linked to changes in gross anatomy and/or histology, as well as hormonal 
changes, which is indeed very specific for men and rats (Wistuba et al. 2003). In both, the 
embryologic prostate develops from the endodermal urogenital sinus, different to other 
reproductive organs such as epididymis or seminal vesicles that originate from the 
mesodermal Wolffian duct (Prins and Lindgren 2015; Wolfertstetter et al. 2013). In first place 
dihydrotestosterone (DHT) is the predominant androgen responsible for the normal prostate 
development, proven by administration of 5-α reductase inhibitors, which results in 
malformations and abnormal prostate growth (Bowman et al. 2003; Imperato-McGinley et al. 
1986). During the early stages of differentiation, estrogen action was found to be present in 
developing stromal cells as well as glandular epithelium (Prins et al. 1998).  
 
Prenatally the rat prostate develops in three defined stages, known as bud stage, bud-tubular 
stage and acino-tubular stage. At the bud-tubular stage (around embryonic day 16), 
myofibroblasts of mesenchymal origin are already present co-expressing vimentin and α-
smooth muscle actin (SMA). These early myofibroblasts are also visible in the human 
prenatal prostate (around weeks 23-25) and supposed to be precursors of smooth muscle cells 
and fibroblasts, the two most dominant cell types of the prostatic stroma (Shaw et al. 2008; 
Bierhoff et al. 1997). The last stage just finishes at postnatal day 28, reasonable for the 
rudimentary developed prostate at birth (Picut et al. 2018). After completion of the acino-
tubular stage, prostate glands are histologically identical compared to adult ones and even 
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start secretion. The last step in prostate development is characterized by an overall growth in 
size until it reaches adult size around postnatal day 43 to 46, which continues even after 
sexual maturity (Dreef et al. 2007).  
 
Development of the human prostate starts earlier compared to rat, during the 2nd trimester of 
pregnancy and is almost finished at birth. Human prostate glands even start secretion 
prenatally. Initial secretion occurs at gestational week 14 and is triggered by androgens, 
primarily in the peripheral zone, whereas the central zone undergoes squamous metaplasia. 
Primordia of the prostate gland appear at gestational weeks 10 to 12, forming epithelial 
outgrowths (prostatic buds) The surrounding stroma differentiate from mesenchymal cells and 
form a lamina propria of the primitive glands (Kellokumpu-Lehtinen 1985). The fetal prostate 
consists of five anatomical lobes described as anterior, posterior, middle and two lateral lobes 
until gestational week 20. Shortly after two lobes regress and the remaining three major 
prostate zones continue to develop (Lowsley 1912). All zones undergo squamous metaplasia 
of the tubule epithelium until birth, mediated by in utero estrogens. Due to the fact, that the 
human prostate is well-developed at the time of birth, postnatal changes are mainly observed 
during puberty, in which a rapid growth of the prostate occur caused by a pubertal surge in 
testosterone production (Picut et al. 2018).  
      
The dorsolateral aspect of the urogenital sinus will develop the dorsal and lateral lobes. In 
contrast, the anterior prostate emerges from four large buds that grow cranially into the 
mesenchyme of the seminal vesicle (Cunha et al. 1987).  
 
Prostatic ducts of the human fetus grow fast in length and branching, starting at gestational 
week 10. Within only three weeks, approximately 70 primary ducts emerge and secretion 
begins. For some time after birth, the second period of ductal growth occurs during puberty, 
similar to glandular development (Brechka et al. 2016; Cunha et al. 1987).     
 
1.3   Neurophysiology of noradrenaline-induced SMC contractions 
Numerous fibers of the autonomic nervous system permeate the prostate. In human, the 
innervation is ensured by the plexus prostaticus, which originates from the plexus 
hypogastritus inferior. The extensive nerve supply of the human prostate exhibits the greatest 
density of nerve fibers in the proximal central aspect, followed by the distal prostate and 
anterior capsule, whereas the innervation of the periphery is very sparse (Chapple et al. 1991). 
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Long postganglionic nerve fibers follow and innervate prostatic blood vessels. Smooth muscle 
cell innervation is mediated by short postganglionic fibers. Cell bodies within the ganglia of 
those fibers are in close proximity to the prostate, characteristic for male accessory glands in 
contrast to other organs, innervated by the sympathetic adrenergic nerve system (Spring-Mills 
and Hafez 1980).  
 
In both, men and rodents the two divisions of the autonomic nervous system play its own role 
during normal prostate physiology. Stimulation of the cholinergic parasympathetic system 
mediates secretion of the prostatic fluid, whereas the noradrenergic sympathetic division is 
responsible for the expulsion of the fluid into the urethra (Prins and Lindgren 2015; Marinese 
et al. 2003). The sympathetic catecholamine noradrenaline operates as a neurotransmitter and 
activates α1-adrenoceptors for smooth muscle contraction during emission (Tong et al. 1996; 
Lepor et al. 1990).  
 
To ensure contractions in prostatic SMCs, polymerized actin needs to be available as 
filaments that anchor to the cell membrane and myosin light chain (MLC) need to be 
phosphorylated. MLC phosphorylation is increased by activation of MLC kinase or inhibition 
of MLC phosphatase (Somlyo et al. 1999).   
 
Activation of α1-adrenoceptors triggers three well-known signaling cascades: calcium, protein 
kinase C and Rho kinase-mediated ones (Fig.3). In addition, α1-adrenoceptors stimulation 
releases receptor-associated, heterotrimeric G proteins from their receptors. G proteins 
typically contain a lager Gα subunit, next to its smaller β and γ subunits.  
 
The Gα subunit is responsible for the activation of GTPase RhoA and phospholipase C (PLC) 
that mediates the formation of the second messengers inositol-1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG) via hydrolyzation of phosphatidylinositol-4,5-bisphosphate (Somlyo 
and Somlyo 2000). IP3, on the one hand triggers a massive intracellular increase of Ca2+ (by 
the opening of Ca2+ channels in the sarcoplasmic reticulum) that binds to Ca2+ dependent 
calmodulin, which is necessary for the calmodulin-dependent MLC kinase to increase the 
MLC phosphorylation (Hennenberg et al. 2014). DAG, on the other hand induces MLC 
phosphorylation by activating isoforms of protein kinase C (PKC) that inhibit MLC 
phosphatase. The third way of action uses RhoA and Rho kinase for inhibition of MLC 
phosphatase that finally causes SMC contraction (Christ and Andersson 2007).       
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1.4   Cyclic guanosine monophosphate signal transduction in SMCs 
1.4.1   General consideration 
The importance of signaling pathways using cyclic guanosine monophosphate (cGMP) as 
second messenger is clearly stated among various investigations, facing certain aspects of 
prostate pathology (Peak et al. 2016; Liu et al. 2016; Peixoto and Gomes 2015; Lythgoe and 
McVary 2013). Amongst others cGMP pathways are involved in neurotransmission, smooth 
muscle contractility as well as proliferation (Hofmann et al. 2006). Within the prostate, cGMP 
is produced by natriuretic peptide membrane receptors with guanylyl cyclase (GC) activity, 
known as GC-A and GC-B (Fig.4).  
Binding of the cardiac hormones atrial natriuretic peptide ANP or BNP to GC-A respectively 
CNP to GC-B activates the synthesis of cGMP. In addition a soluble form of GC (sGC) exists, 
using nitric oxide (NO) for activation that is generated by NO synthases. In either case, 
guanosine triphosphate is converted to guanosine monophosphate by reduction of 
pyrophosphate (Wedel and Garbers 2001). 
Fig.3: Noradrenaline mediated signaling pathways in prostatic SMCs. 
Activation of α1-adrenoceptors mediates smooth muscle contraction by one of three well-known 
signaling pathways: protein kinase C (PKC), Rho kinase or calcium. (DAG) diacylglycerol; (Gα,β,γ) G 
proteins subunit α, β, γ; (IP3) inositol-1,4,5-triphosphate; (MLC) myosin light chain; (PLC) 
phospholipase C; (RhoA) ras homolog gene family, member A. Modified from Hennenberg et al., 
2014. 
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The amount of intracellular cGMP is regulated by phosphodiesterases (PDE), with PDE5 
representing a crucially implicated subtype, that mediates cGMP degradation over hydrolysis 
(Ghofrani et al. 2006). Finally, contractions of SMCs are initiated via activation of the cGMP-
dependent protein kinase I (PKG I), one of the cGMP target proteins (Müller et al. 2011).  
 
It is assumed that PDE5 expression is directly influenced by androgens (Seftel 2005). 
Upregulation of PDE5 expression was found together with a downregulation of PKG I protein 
level in Leydig cells of the rat testis after two weeks of testosterone treatment (Andric et al. 
2010). These observations were only visible in treated animals but lack significant results at 
the cellular level. Therefore, cell culture experiments would have provided a system that is 
less influenced by other regulatory factors or cellular structures.    
 
 
 
Fig.4: cGMP signaling pathway in prostatic SMCs.  
The second messenger cGMP is produced by one of three types of guanylyl cyclase (GC). sGC uses 
nitric oxide (NO) to induce cGMP synthesis while GC-A and GC-B are activated by binding of 
natriuretic peptides (ANP, BNP, CNP). The intracellular amount of cGMP is regulated by hydrolysis of 
phosphodiesterases (PDEs). cGMP activates the cGMP-dependent protein kinase I (PKGI) to mediate 
smooth muscle relaxation.  
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1.4.2   PKG I, a key protein for smooth muscle contractility 
Usually, protein kinases modulate their targets by catalyzing the transfer of phosphates to 
certain amino acids such as serine, threonine or tyrosine that induce conformational changes 
or changes of the target function (Roskoski 2015). They are highly ubiquitous, vary in 
function and target over 30% of all cellular proteins (Tulis 2017).   
 
The cGMP-dependent protein kinase I, in particular, belongs to the serine/threonine kinase 
family and is targeted with high affinity by cGMP. PKGI consists of three functional 
domains. The C-terminal catalytic domain comprises the MgATP- and peptide binding 
pocket. The N-terminal domain features a leucine-isoleucine zipper motif, while the 
regulatory domain contains tandem cGMP-binding sites (Fiedler et al. 2006). 
 
However, the exact mechanism of action that finally results in smooth muscle relaxation after 
activation of PKG I is still unclear (Haynes and Cook 2006). It seems plausible, that 
stimulation of PKG I maintain the opening of large conductance Ca2+ activated K+ channels or 
ATP-sensitive potassium channels (Beech 1997; Alioua et al. 1995). Both events may lead to 
hyperpolarization of the cell membrane and closure of voltage-gated Ca2+ channels. 
Furthermore, intracellular levels of Ca2+ in vascular smooth muscle cells are regulated by 
another PKG I action, which lead to phosphorylation of the sarcoplasmic reticulum protein 
phospholamban (Cornwell et al. 1991). All of this events would finally prevent the 
phosphorylation of MLC, a classic signaling pathway of noradrenaline-induced contractility, 
as described earlier (Haynes and Cook 2006).  
 
1.4.3   PDE5 and its role in the prostate 
PDEs consist of 11 families of enzymes that are able to break phosphodiester bonds. PDE5 is 
described as cGMP-specific phosphodiesterase (McAllister-Lucas et al. 1993). Regulating the 
intracellular level of cGMP, PDE5 is essential for various physiological processes and 
therefore plays a key role as a target enzyme for the treatment of lower urinary tract 
symptoms (LUTS) and benign prostatic hyperplasia (BPH) (Lin et al. 2013). Nowadays PDE5 
inhibitors, namely tadalafil are approved for BPH treatment. Knowledge about the mechanism 
of action of PDE5 inhibition is primarily investigated for smooth muscle tone reduction in 
case of treatment for erectile dysfunction, pulmonary hypertension and BPH (Gacci et al. 
2016; Uckert et al. 2008). PDE5 inhibitors induce smooth muscle relaxation through blocking 
the degradation of cGMP, which leads to an increase of intracellular cGMP. This in turn, 
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activates a cascade of enzymes including PKG I and results in prostatic SMC relaxation, as 
described earlier. Especially the duration of cGMP action is regulated by PDE5, which plays 
an important role in the modulation of oxygenation, inflammation, proliferation and nerve 
activity, besides smooth muscle relaxation (Kügler et al. 2018; Gacci et al. 2016; Juilfs et al. 
1999). In addition, vascular SMC relaxation may improve blood flow to the lower urinary 
tract (Carson et al. 2014).   
 
In both, rodent and human prostate tissue, the exact localization of PDE5 is still under 
discussion. Early studies of the human prostate state PDE5 expression to be present in 
glandular and subglandular areas of the transition zone, predominantly in glandular regions 
and less in stromal parts (Uckert et al. 2006; Uckert et al. 2001). Later investigations of the 
transition zone suggest PDE5 localization in smooth muscle cells of the prostate glands, co-
localized with its substrate cGMP (Ückert et al. 2013; Giuliano et al. 2013), but not in the 
epithelium (Fibbi et al. 2010). Furthermore, PDE5 expression in the human prostatic 
vasculature is shown for the endothelial and smooth muscle layer of the vesicular-deferential 
artery (Morelli et al., 2011). PDE5 localization in rat prostate is even more controversial. 
Some reveal PDE5 immune reactivity exclusively within the fibromuscular stroma (Zhang et 
al. 2015), in contrast to findings that show the gland epithelium positively stained together 
with their surrounding SMCs (Wang et al. 2015b). Expression of  PDE5 in rat prostatic blood 
vessels is reported for vascular SMCs embedded into the tunica media (Peuler and Phelps 
2015). However, none of the previous studies had focused on PDE5 expression in SMCs of 
the prostatic ducts alone, separated from those of the prostate glands. Taken this into account 
could be a crucial factor in BPH treatment, especially since a typical negative side effect of 
other BPH therapeutics, such as α1-adrenergic blockers, is abnormal and decreased 
ejaculation (Kügler et al. 2018; Kaplan 2009; Chapple 2004). 
 
1.4.4   Further cGMP-specific PDEs 
Apart from PDE5, PDE6 and PDE9 also specifically hydrolyze cGMP with high affinity. 
PDE6 plays an important role as a key component in the visual transduction cascade by 
regulating the amount of cGMP in rod and cone photoreceptor cells of the retina. This was 
demonstrated by mutations of the PDE6β gene in mouse rod cells that causes an intracellular 
increase of the cGMP level of those cells (Wen et al. 2014; Bowes et al. 1990). Interestingly, 
PDE6 knockout mice develop fully functional retina and reproduce normally (Zhang et al. 
2014). Outside the retina, subtypes of the PDE6 are present in lung and its vasculature, as well 
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as human embryonic kidney (Murray et al. 2003). In addition, PDE6 expression found in 
human alveolar epithelial cells could provide a potential target for the treatment of idiopathic 
pulmonary fibrosis (Nikolova et al. 2010).  
 
PDE9 targets cGMP with the highest affinity among all PDE families. Until now only one 
isoform, PDE9α is known. Knockout of PDE9 in mouse resulted in a reduction of the body 
weight, body fat and insulin resistance. Inhibition of PDE9 increases the cGMP level in the 
central nervous system together with an increased learning and memory capability (Deninno 
et al. 2009; van der Staay et al. 2008; Liu et al. 2008). Other tissues that express PDE9 are 
kidney, lung, liver and heart (Keravis and Lugnier 2012). In isolated myocytes of the human 
heart, PDE9 was found to regulate cGMP signaling apart from the nitric oxide pathway and is 
considered as a possible target in case of stress-induced heart diseases (Lee et al. 2015).  
 
1.5   Prostate pathology 
1.5.1   Prostate cancer 
Prostate cancer is noticed to be the second most frequent cancer among men worldwide 
(Bruinsma et al. 2017). Estimates state that 1.1 million new cases have occurred in 2012 with 
the highest incidence rates in developed countries such as Australia/New Zealand, Northern 
America and Europe (Torre et al. 2015). Predictions for 2030 expect that the global incidence 
of prostate cancer will increase by 1.7 million and death increase by 0.5 million (Ferlay et al. 
2010). Due to this, prostate cancer represents tremendous health and economic burdens 
(Wang et al. 2018). 
 
In most cases (around 70%) prostate cancer develops from the peripheral zone. 
Approximately 10-20% emerges from the transition zone and only 1-5% arises from the 
central zone (Pizzuto et al. 2018). On a cellular basis, it is widely accepted that 
adenocarcinoma of the prostate arises from the epithelia of the glands. The prostatic 
epithelium consists of basal and luminal cells, interspersed with some neuroendocrine cells 
and is surrounded by stroma cells, such as (myo-) fibroblasts, smooth muscle cells, vascular 
endothelial cells or nerve fibers that transmit signals for epithelium regulation (Tyekucheva et 
al. 2017). Studies in mouse suggested at least three different prostate epithelial progenitor 
populations but were not able to clarify which one induces prostate cancer (Ousset et al. 2012; 
Wang et al. 2009). Apart from the proliferative epithelial component of the gland, stromal 
cells are more and more suspected to contribute to carcinogenesis and cancer progression 
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(Tuxhorn et al. 2002b; Olumi et al. 1999). However, inflammatory myofibroblastic tumors of 
the prostate are extremely rare as only two cases have been reported since 2012 (Zeng et al. 
2018).  
 
Another rare type of prostate cancer is known as (intra-) ductal carcinoma, a malignant 
epithelial proliferation that arises from primary periurethral prostatic ducts (Böttcher et al. 
2018; Baig et al. 2015). Ductal carcinomas are reported to be quite aggressive due to high 
Gleason score, advanced tumor stages, biochemical relapse and distant metastasis (Chen et al. 
2015; Kimura et al. 2014; Watts et al. 2013).   
 
Non-metastasized cancer is often removed by either radical prostatectomy or radiation 
therapy. Common long-term side effects of both therapies are incontinence and impotence, 
often treated with PDE5 inhibitors (Prins and Lindgren 2015). Apart from that, administration 
of the PDE5 inhibitor sildenafil was observed during growth and metastasis of human prostate 
cancer cells, inoculated in a nude mouse model. Even daily sildenafil administration did not 
promote primary tumor growth or metastasis (Qian et al. 2003). However, the cGMP 
producing enzyme sGC was also shown to mediate prostate cancer cell proliferation, 
regulated by androgens (Cai et al. 2007). Because cGMP signaling pathways are known to 
regulate cell proliferation and therefore contribute to tumor development, therapeutics based 
on cGMP pathway components might not be a rewarding option (Bian and Murad 2014).                     
 
Other strategies to slow cancer development are associated with regulation of sex hormones. 
Androgen deprivation therapy initially stops the progression of prostate cancer, but often turns 
into an androgen-independent disease that progress after 12 to 36 months (Green et al. 2012; 
Crawford et al. 1989). There is also strong evidence of estrogens been involved in 
carcinogenesis and cancer progression, mediated by in situ estrogen production and estrogen 
receptor signaling (McPherson et al. 2010; Ricke et al. 2008). However, regulation of the 
intra-prostatic androgen and estrogen level may interact with certain cGMP pathway 
components, influencing the efficacy of those potential treatment targets. 
 
 
 
 
 
Introduction 
20 
 
1.5.2   Benign prostatic hyperplasia 
Second to prostate cancer, benign prostatic hyperplasia (BPH) represents the other main 
growth disorder in the prostate affecting approximately 50% of men at the age of 60, up to 
80% of men at the age of 80 or older and is often associated with painful bladder outlet 
obstructions (van Asseldonk et al. 2015). The transition zone is reported as the main site of 
origin for prostatic hyperplasia, whereas the central zone is considered to be BPH resistant 
(Prins and Lindgren 2015). However, prostatic enlargement is a true hyperplastic and not a 
hypertrophic process, which means a net increase in cell number, not cell size (McNeal 1990). 
This increase in cell number is assumed to be a result of epithelial and stromal proliferation 
respectively impaired programmed cell death that finally cause cellular accumulation 
(Roehrborn 2008). In primarily small-resected glands a predominance of the fibromuscular 
stroma was clearly shown (Shapiro et al. 1992). Another study demonstrated that the relative 
amounts of SMCs and fibroblasts in the human prostate are increasing with old age and 
presence of BPH (Sensibar et al. 1999). This study also revealed a BPH-related increase of 
growth rate in cultured human prostate SMCs which might reflect programmed cellular 
responses to hormones and growth factors.  
 
It is widely accepted, that (active) smooth muscle tone plays a major role in the 
pathophysiology of BPH (Roehrborn and Schwinn 2004). Muscle tone in the prostate is 
regulated by the adrenergic nervous system. It is suggested that the overactivity of the 
autonomic nervous system contributes to BPH development (McVary et al. 1994). Further 
studies on receptor binding demonstrated α1adrenoceptor to be the most abundant 
adrenoceptor subtype present in the human prostate (Yamada et al. 1994; Lepor et al. 1993). 
Treatment of BPH using α1-adrenergic blockers has proven to be a potent strategy to mediate 
urethral pressure reduction and to increase urine flow rate. Alpha blockers such as prazosin or 
doxazosin act as inverse agonists to inhibit α1-receptors and finally reduce smooth muscle 
tone of the prostate and bladder neck (Kaplan 2008). But treatment with alpha blockers is 
associated with common side effects like disturbed ejaculation. Therefore, PDE5 inhibitors 
represent a potent therapeutic alternative (Kügler et al. 2018). PDE5 inhibitors such as 
sildenafil or tadalafil mediate reduction of detrusor muscle overactivity in the bladder neck as 
well as relaxation of prostatic SMCs by increasing intracellular cGMP (Filippi et al. 2007; 
Roehrborn 2004). In addition, vascular smooth muscle relaxation through PDE inhibition 
might also contribute to BPH treatment by improved blood flow (Carson et al. 2014).     
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Apart from humans only dogs and some primates are known to develop naturally occurring 
BPH (Christensen 2018). Therefore plenty of strategies are pursued to induce BPH in rats 
such as inbreeding of Wistar-Kyoto rats or administration of inflammatory substances like 
formalin, testosterone, sulpiride or even specific microbial strains as inflammation promotes 
the establishment of BPH. (Da Silva et al. 2018; Wang et al. 2015c; Chung et al. 2015).  
 
However, BPH development and maintenance is furthermore associated with the occurrence 
of sex steroid hormones and their receptors. Androgens are in focus of interest for clinical 
investigations because they are considered to be involved in proliferation, differentiation, 
morphogenesis and functional maintenance (Wen et al. 2015). Steroid metabolism in the 
prostate is ensured by 5α-reductase (type II), which catalyzes the reduction of testosterone to 
the more potent dihydrotestosterone (DHT). 5α-reductase inhibitors are another option for 
BPH treatment, mediating a decrease of DHT serum level together with slow progression of 
clinical BPH (Parsons 2010). Other than androgens, there is increasing evidence of estrogens 
to be effecting important mechanisms that contribute to prostatic cell growth while the 
molecular mechanisms for estrogen action during BPH pathophysiology remain unclear (Lee 
and Kuo 2017; Nicholson and Ricke 2011). 
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2 Aim of the study 
 
This study aims to reveal the cellular localization of cGMP pathway components with special 
focus on the cGMP degrading protein PDE5 as well as the cGMP target protein PKG I. 
Comparisons between rat, mouse and human prostatic tissue attempt to validate possible 
similarities and/or differences. For this purpose, classical immunostaining will be combined 
with a modified approach, based on the novel CLARITY method to gain a better 
understanding of the prostatic architecture.  
 
A subsequent step will be the visualization of cGMP effects. Time-lapse imaging will be used 
to illustrate prostatic contractility in rat and human tissue. It is planned to investigate possible 
regulatory effects of the PDE5 inhibitor sildenafil in this experimental setup.  
 
Finally, attempts will be made to analyze the underlying mechanisms and therapeutic 
relevance of hormone regulation in cGMP pathways, involving experiments on both, rodents 
and humans. For this, histological investigations will use castrated rats as well as mouse 
models that contain a genomic aromatase knockout or aromatase overexpression. In addition, 
age-dependent changes will be tested by postnatal and adult rats. For comparisons with rodent 
tissue, testosterone effects on isolated and cultured interstitial cells of the human prostate will 
be analyzed  
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3 Materials & Methods 
 
3.1   Materials 
3.1.1   Devices 
Agarose gel electrophoresis system   PeqLab, Erlangen, Germany 
Automated cell counter TC 10   Bio-Rad, Munich, Germany 
Centrifuge 5804 R      Eppendorf, Hamburg, Germany 
Confocal laser scanning microscope LSM 710 Zeiss, Munich, Germany 
Elisa Reader      Dynatech, Denkendorf, Germany 
Fluorescence microscope, Axioskop 2 plus  Zeiss, Munich, Germany 
High-temperature Incubator    Heraeus, Hanau, Germany 
iCycler IQ™ Real-time PCR detection system Bio-Rad, Munich, Germany 
Microscope Axiostar plus    Zeiss, Munich, Germany 
Microtome, RM2255     Leica, Wetzlar, Germany 
Nanodrop 2000 Spectrometer   Thermo Scientific, Waltham, USA 
Nuaire™ Bench Class II together with  IBS Integra Bioscience, Fernwald,  
Nuaire™ DH Autoflow CO2 Air Incubator  Germany 
Polyacrylamide gel electrophoresis system  Hoefer, San Francisco, USA 
Power supply      Hoefer, San Francisco, USA 
Safety Cabinet     Koettermann, Uetze, Germany 
SonoPlus mini 20 ultrasonic homogenizer  Bandelin, Berlin, Germany 
Spectrophotometer, Biophotometer   Eppendorf, Hamburg, Germany 
Transillumination microscope BX50WI  Olympus, Tokio, Japan 
 
3.1.2   Kits 
Amersham™ ECL WB detection system  GE Healthcare, Freiburg, Germany 
Bio-Rad protein assay     Bio-Rad, Munich, Germany 
EnVision+System, Peroxidase (DAB) kit  DAKO, Hamburg, Germany 
GeneAmp® RNA PCR kit    Applied Biosystems, Darmstadt, Germany 
Horseradish peroxidase labeled polymer  DAKO, Hamburg, Germany 
iScript™ cDNA synthesis kit   Bio-Rad, Munich, Germany 
Platinum® SYBR® Green qPCR SuperMix-UGD Invitrogen, Karlsruhe, Germany 
RNeasy Micro kit     Qiagen, Hilden, Germany 
RNeasy Mini kit      Qiagen, Hilden, Germany 
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3.1.3   Consumables 
Amersham™ Hybond™ -nitrocellulose   GE Healthcare, Freiburg, Germany 
membranes 
Automat Star coverslips     Engelbrecht, Edermünde, Germany 
Blue tack      Bostik, Wauwatosa, USA 
Cell culture plates (6 well, 24 well, 96 well)  Greiner bio-one, Frickenhausen, Germany 
Cell Scraper      BD Falcon, Heidelberg, Germany 
Cell star tubes (25 ml, 50 ml)   Greiner bio-one, Frickenhausen, Germany 
Delta T dish      Bioptechs, Buttler, USA 
Eppendorf tubes (0.5 ml, 1.5 ml, 2 ml)  Eppendorf, Hamburg, Germany 
Filter tips      Eppendorf, Hamburg, Germany 
Flasks (T75, T175)     Greiner bio-one, Frickenhausen, Germany 
Parafilm      Bemis NA, Neenah, USA 
PCR tubes (0.2 ml)     Eppendorf, Hamburg, Germany 
Pipettes (10 µl, 20µl, 100 µl, 1000µl)  Gilson, Middleton, USA 
Serological pipettes (5 ml, 10 ml, 25 ml, 50 ml) BD Falcon, Heidelberg, Germany 
SuperFrost® Plus microscope slides  R. Langenbrinck, Emmendingen, 
Germany 
X-ray films      Fuji, Tokio, Japan 
 
3.1.4   Reagents 
2,2′-Azobis(2-methylpropionamidine)  Sigma-Aldrich, Steinheim, Germany 
dihydrochloride  
3,3′-Diaminobenzidin (DAB)   Merck, Darmstadt, Germany 
4′,6-Diamidin-2-phenylindole (DAPI)  Merck, Darmstadt, Germany 
Acrylamide solution, Rotiphorese Gel 30  Roth, Karlsruhe, Germany 
Agarose      PeqLab, Erlangen, Germany 
Ammonium persulfate (APS)   Roth, Karlsruhe, Germany 
AmpliTaq DNA polymerase    Applied Biosystems, Darmstadt, Germany 
Aniline blue      Merck, Darmstadt, Germany 
Azocarmine      Chroma, Stuttgart, Germany 
Bisacrylamide      Roth, Karlsruhe, Germany 
Boric acid      Roth, Karlsruhe, Germany 
Bovine serum albumin (BSA)   Sigma-Aldrich, Steinheim, Germany 
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Bromophenol blue     Sigma-Aldrich, Steinheim, Germany 
Calcium chloride     Merck, Darmstadt, Germany 
Di-sodium hydrogen phosphate   Roth, Karlsruhe, Germany 
Dithiothreitol (DTT)     Invitrogen, Karlsruhe, Germany 
DNAase-1      Applied Biosystems, Darmstadt, Germany 
Ethanol      Riedel de Haen, Seelze, Germany 
Ethylenediaminetetraacetic acid (EDTA)  Roth, Karlsruhe, Germany 
Glacial acetic acid     Merck, Darmstadt, Germany 
Glucose oxidase     Sigma-Aldrich, Steinheim, Germany 
Glycerol      Roth, Karlsruhe, Germany 
Glycerine      Roth, Karlsruhe, Germany 
Hepes       Sigma-Aldrich, Steinheim, Germany 
Hematoxylin      Merck, Darmstadt, Germany 
Histodenz      Sigma-Aldrich, Steinheim, Germany 
Hydrochloric acid      Merck, Darmstadt, Germany 
Hydrogen peroxide     Roth, Karlsruhe, Germany 
Isopropanol      Sigma-Aldrich, Steinheim, Germany 
Magnesium chloride     Merck, Darmstadt, Germany 
Methanol       Fluka, Buchs, Switzerland 
Minimal essential medium (MEM)   Gibco, Invitrogen, Karlsruhe, Germany 
TEMED      AppliChem, Darmstadt, Germany 
Nickel sulfate      Merck, Darmstadt, Germany 
Noradrenaline      Sigma-Aldrich, Steinheim, Germany 
Normal goat serum     Sigma-Aldrich, Steinheim, Germany 
Page ruler™ Plus     Thermo Fisher Scientific, Waltham, USA 
Paraformaldehyde (PFA)    Roth, Karlsruhe, Germany 
Phosphotungstic acid     Riedel de Haen, Seelze, Germany 
Picric acid      Fluka, Buchs, Switzerland 
Ponceau S solution     Sigma-Aldrich, Steinheim, Germany 
Sigma Marker™ wide range    Sigma-Aldrich, Steinheim, Germany 
Skimmed-milk     Roth, Karlsruhe, Germany 
Sodium chloride     Roth, Karlsruhe, Germany 
Sodium dodecyl sulfate    Roth, Karlsruhe, Germany  
Sodium deoxycholic acid    Sigma-Aldrich, Steinheim, Germany 
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Sodium hydroxide      Merck, Darmstadt, Germany 
Sodium azide      Sigma-Aldrich, Steinheim, Germany 
Thimerosal      Sigma-Aldrich, Steinheim, Germany 
Tris       Roth, Karlsruhe, Germany 
Tri-sodium citrate dehydrate    Merck, Darmstadt, Germany 
Triton X-100      Sigma-Aldrich, Steinheim, Germany 
Tween 20      Sigma-Aldrich, Steinheim, Germany 
Western blocking reagent    Roche, Mannheim, Germany 
Xylene      Roth, Karlsruhe, Germany 
β-mercaptoethanol      Sigma-Aldrich, Steinheim, Germany 
 
3.1.5   Inhibitors 
Aprotinin (trypsin inhibitor)    Roth, Karlsruhe, Germany 
Leupeptin (protease inhibitor)   Roth, Karlsruhe, Germany 
Phenylmethanesulfonyl fluoride (serine   Sigma-Aldrich, Steinheim, Germany 
protease inhibitor) 
Sildenafil (PDE5 inhibitor)    Pfizer, New York, USA 
 
3.1.6   Primary antibodies 
Anti-calponin-1 Rabbit monoclonal  Epitomics, California, USA 
Anti-Ki67  Rabbit polyclonal  Novocastra, Newcastle, UK 
Anti-PDE5  Rabbit polyclonal  Laurinda Jaffe, University of Connecticut  
Health Center, Farmington, USA 
Anti-PKG I  Rabbit polyclonal  Enzo Life Sciences, Lörrach, Germany 
Anti-sGC (β1)  Rabbit polyclonal  CAYMAN, Ann Arbor, USA 
Anti-SMA  Mouse monoclonal  Sigma-Aldrich, Steinheim, Germany 
Anti-vinculin  Mouse monoclonal  Sigma-Aldrich, Steinheim, Germany 
Anti-α-tubulin  Mouse monoclonal  Sigma-Aldrich, Steinheim, Germany 
 
3.1.7   Secondary antibodies 
Goat-anti-mouse IgG     Pierce, Bonn, Germany 
Goat-anti-rabbit IgG     Pierce, Bonn, Germany 
Cy3 anti-rabbit IgG     Jackson ImmunoResearch, Grove, USA 
Alexa Fluor 488 anti-mouse IgG    Thermo Fisher Scientific, Waltham, USA 
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3.2   Methods 
3.2.1   Tissues and Cells 
3.2.1.1   Rodent prostate 
Male Wistar rats were housed at the animal facilities of the Justus-Liebig University Giessen, 
with access to food and water ad libitum. Rats were anesthetized with 5% isoflurane and 
sacrificed via cervical dislocation. According to age, animal groups were divided into adult 
(older than 2 months) and postnatal (day 4 to 6 after birth) rats. Subsequent preparation of the 
prostatic ventral lobes was performed within the next 1 to 2 hours (Fig.5). The urogenital tract 
containing bladder, prostatic urethra, seminal vesicles, ductus deferens and the entire prostate 
was removed from the rat torso and transferred to minimal essential medium (MEM) for 
further dissection. Removal of fat and the thin prostatic capsule was necessary to distinguish 
between the four different prostate lobes (Fig.5A). Ventral prostatic ducts which drain into the 
ventral aspect of the urethra were severed in close proximity to the urethra (Fig.5B). Distal 
prostate glands were separated (Fig.5C) and dissected from connective tissue. Glands and 
ducts were finally embedded for anatomical investigations or prepared for time-lapse imaging 
studies.  
 
 
 
 
 
In addition, paraffin-embedded and frozen prostate tissue of genetically modified adult mice 
was obtained from the animal facilities of the Monash University Melbourne. The first mouse 
model in this study contained an aromatase knockout (ArKO) through targeted disruption of 
the cyp19 gene, leading to an estrogen-deficiency in these mice. By breeding of male and 
female mice heterozygous for cyp19, homozygous aromatase +/+ or -/- offspring was 
Fig.5: Dissection of the rat ventral prostate. 
A: Ventral view of the lateral (lp) and ventral (vp) prostatic lobes which drain into the urethra (u) beneath the 
bladder (bl), seminal vesicle (sv) and ductus deferens (dd). B: Magnification of the left ventral lobe, 
highlighting prostatic ducts (d), glands (g) and blood vessels (v). C: Magnification of five adjacent prostatic 
glands. Scale bars (A) 2mm, (B) 1mm, (C) 0,5 mm 
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produced. Day of birth was defined as day 0. Genotyping of male offspring was performed 
using tail DNA for PCR analysis (Bianco et al. 2006).  
 
The second mouse model in this study showed overexpression of aromatase (AROM+) in 
most organs such as brain, testis, prostate, heart and liver (Jazbutyte et al. 2012). For this a 
purified expression vector for human P450 aromatase (pUBC-AROM) was constructed, using 
the pRC/CMV plasmid as backbone. The cytomegalovirus promoter of the vector was 
replaced by a 1.0-kb ubiquitin C promoter and raised on FVB/N background (Bell et al. 2014; 
Li et al. 2001).  
 
Tissue collection, housing and transport followed the guidelines for animal care and were 
approved by the committee for laboratory animals of Justus-Liebig-University Giessen (rats: 
JLU no. 469_M, 510_M, 527_AZ and 580_M; mice: MARP/2011/070/BC, PC1-N18/11 and 
PC1-N52/13).  
 
3.2.1.2   Human prostate 
Human tissue samples originated from patients aged between 60 to 79 years (medium 71.7 
±6.5 years) which underwent either transurethral monopolar electroresection of the prostate 
(TUR-P) for BPH treatment or radical prostatectomy (RP) in case of prostate cancer at the 
Department of Urology, Pediatric Urology and Andrology of the Justus-Liebig-University 
Giessen.  
 
None of the patients received any previously recorded hormone therapy. Tissue samples from 
TUR-P were collected periurethral, while tissue samples from radical prostatectomy 
originated from the peripheral aspect of the prostate. Biopsies were stored for a short time (up 
to 1 hour) in minimal essential medium at 4 °C before being dissected into sections thinner 
than 0.5 mm allowing transillumination to perform time-lapse imaging and anatomical 
investigations.      
 
All patients gave written informed consent before surgery. Usage of human prostate tissue 
was approved by the ethics committee of the Medical Faculty, Justus-Liebig-University 
Giessen (ethical vote 49/05, 2005) 
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3.2.1.3   Human interstitial cells 
A total of 6 human interstitial cell lines were isolated from prostate tissue of 3 different cancer 
patients (105 R, 107 R, 128 R), who underwent radical prostatectomy. With the permission of 
all patients, tissue samples of each prostate were dissected from 2 different regions located 
proximal respectively distal to the carcinoma area.  
 
Patients gave written informed consent before surgery. Use of human prostate tissue was 
approved by the ethics committee at Monash University (2004/145). 
 
3.2.2   Cell culture 
A testosterone-enriched medium was used to isolate human prostatic interstitial cells and 
subsequently stored in dimethyl sulfoxide (DMSO) at liquid nitrogen. Frozen cell lines were 
brought up to cell culture by slowly disperse toxic DMSO, starting at passage 4 to 5 in T75 
flasks. All cells were cultured at 37 °C, under 5% O2 and 5% CO2 in 15ml testosterone-
enriched cell growth medium with FCS. The medium was renewed every 2 to 3 days. If cell 
growth reached at least 90% confluency, cells were reseeded in T175 flasks. Next time when 
cell growth reached total confluency, cells got passaged.   
 
Passaging always included the following steps. First, the old growth medium was exhausted, 
followed by a washing step with 10ml PBS+EDTA for 5 min at room temperature (RT). After 
aspirating the PBS, 2 ml of trypsin (0,1%) was added and incubated for 5min at 37 °C. 
Trypsin was neutralized by adding of 5 ml medium with FCS and this cell suspension was 
then transferred into a 15 ml tube and spun down at 1000 rpm for 5 min at RT. The 
supernatant was aspirated and the remaining cell pellet was resuspended into 6 ml medium. 
After cell counting with the help of a TC 10 automated cell counter (Bio-Rad, Munich, 
Germany), the cell suspension was split in half and added to 17ml medium within two new 
T175 flasks, containing at least 1x106 cells. 
 
Tissue collections, cell isolation as well as all necessary cell culture experiments were 
performed at the facilities of the Department of Anatomy and Developmental Biology, 
Monash University, Melbourne, Australia.   
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3.2.2.1   Dihydrotestosterone treatment 
Cell culturing continued until cell lines reached passage 7 to 8, containing a minimum of 
6x106 cells per cell line. The day before DHT treatment, all cells were trypsinized and 
counted. Cells were resuspended in phenol red-free medium that contained no testosterone to 
avoid false responses. 2 ml phenol red-free medium together with 5x105 cells within each well 
were seeded in triplicates (Fig.5). Cells were allowed to recover under normal culturing 
conditions overnight.  
 
 
 
In addition, a 96-well plate was seeded with 5x103 cells per well from all investigated cell 
lines (10 replicates) for later immunohistochemistry. The following day medium was 
exchanged by 1.9 ml fresh phenol red-free medium. To get a final concentration of 15 µM 
DHT, 100 µl of a 300 µM DHT stock solution was added to each well, respectively 100 µl of 
a 1 µM DHT stock solution to reach a final concentration of 10 nM DHT. For vehicle control 
a stock solution of 300 µl DMSO dissolved in 700 µl medium was produced and 100 µl of it 
was added to each vehicle replicate, resulting in 15 µM final concentration. DHT incubation 
took 24 hours under normal culturing conditions, as described earlier (see 3.2.2 cell culture). 
 
After 24 hours the medium was aspirated and pure PBS was added to wash the remaining 
cells on the bottom of the wells. PBS from all triplicates of one experimental setup was 
aspirated. Subsequently, cells of all three replicates were resuspended in 500 µl of 
mercaptoethanol solution (1%) with the help of a cell scraper, collected in 1.5 ml tubes and 
finally stored at -80°C.  
 
 
 
Fig.6: Seeding template for human prostatic interstitial cells. 
All cell lines (total of 6) were seeded as triplicates into 6-well plates and allowed to regenerate overnight before 
treatment with DMSO (vehicle control), 15 µM DHT or 10 nM DHT started.   
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3.2.3   Real-time PCR 
3.2.3.1   Purification of total RNA 
Isolation of total RNA from all collected cells was performed using the RNeasy Mini Kit 
(Qiagen, Hilden). In a first step, lysed cells were spun down with 10,000 rpm. The 
supernatant was exchanged with 70% ethanol, mixed and transferred to an RNeasy spin 
column. Washing and RNA purification proceeded according to manufacturer's instructions 
until RNA was eluted into 40 µl RNase free water. Samples were stored again at -80 °C.  
 
3.2.3.2   First-strand cDNA synthesis 
According to the amount of RNA of each sample, measured by NanoDrop system (Thermo 
Scientific, Waltham, USA), 500 ng of RNA was incubated on 65 °C together with 50 ng/µl 
Random Hexamer and 10 mM dNTPs for 5 min to remove secondary structures. The solution 
was allowed to cool down and incubated with 1 µl RNaseOUT Recombinant RNase Inhibitor 
at 25 °C for 5 min. Superscript III Reverse Transcriptase was used for cDNA synthesis. For 
this step, the samples were incubated within the thermocycler at 50 °C for 1 hour. The 
reaction was inactivated by heating up to 70 °C for 15 min. All samples were diluted (1:10) in 
200 µl nuclease free water and stored at -20 °C. 
 
3.2.3.3   Primer design 
Except for α-SMA, all primers were self-designed by using the following procedure. For each 
gene listed below (Tab.1) the complete nucleotide sequence was searched online from the 
NCBI database.  
 
 
Gene name Primer position Primer sequence Annealing temp  PCR product lengh [bp] Origin 
sGC (β1) 1470 (fwd) 5'-TGCTGGCCAGGTTCAAGTAG-3' 59,96 142 self designed 
  1611 (rev) 5'-TGTTCGGCTTGTGAGGTTGA-3' 59,82     
PDE-5 2835 (fwd) 5'-TATGCCTAGTTTCTTACACACTGTC-3' 58,6 190 self designed 
  3024 (rev) 5'-GTGCTAACAGTGGATGTTGTTGAT-3' 59,78     
PKG I 1330 (fwd) 5'-GTTGGAGGTTTCGGACGAGT-3' 59,97 118 self designed 
  1447 (rev) 5'-GGATGTGCTCCTGCTGTCTT-3' 60,04     
α-SMA 537 (fwd) 5'-TGTAAGGCCGGCTTTGCT-3' 59,57 112 Madar et al. 2009 
  648 (rev) 5'-CGTAGCTGTCTTTTTGTCCCATT-3' 59,5     
 
The official NCBI homepage also provides a free online Basic Local Alignment Search Tool 
(BLAST) that was used to either test potential primer sequences or design them, featuring the 
Tab.1: Human-specific primer descriptions.                                                                                                     
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following characteristics, ordered by importance. Chosen primers were able to detect all 
splicing variants of a certain gene, without detecting further nucleotides and had a product 
length around 150 bp, a melting temperature close to 60 °C, a self-complementary factor 
below 5 as well as a GC percentage around 50%. Primers were ordered from Eurofins MWG-
Biotech (Ebersberg). A stock solution of 200 pM/µl was produced for usage in real-time PCR.  
 
3.2.3.4   Real-time PCR set up and conditions 
The polymerase chain reaction, short PCR enables to multiply a DNA sequence of interest, 
targeted by specific primer pairs. DNA replication is achieved by exposing the reactants to 
cycles of repeated heating and cooling which control temperature-dependent reactions, 
necessary to melt and replicate DNA. In case of real-time or quantitative PCR (qPCR), 
products are additionally labeled with fluorescence markers, to quantify the amplified amount 
of DNA copies. The number of cycles is counted in which the detectable fluorescence of an 
amplified PCR product that exceeds the background fluorescence and printed as Ct value.   
 
Power SyBr Green PCR Master Mix was produced and incubated with triplicates of the 
cDNA templates. qPCR was always performed with the following composition.  
 
 
Component Volume [µl] for 1 sample 
Power SYBR Green Master Mix 12.5 
10µM fwd primer 0.5 
10µM rev primer 0.5 
Template 5 
Water 6.5 
Total 25 
 
The amplification for all genes of interest used the following conditions. 
 
 
Temperature [°C] Duration [sec] 
95 600 
95 20 
60 20 
72 20 
50 30 
20 ∞ 
 
                                  Tab.2: Template for qPCR loading. 
Tab.3: Template for qPCR conditions                                                            
Heating step 2 to 4 were repeated for 50 cycles.   
50 Cycles 
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To compare Ct values of the genes listed in Table 1, values were normalized by using the 
ΔCt-method (Huggett et al. 2005). The expression ratio is calculated, relative to a second 
(housekeeping) gene, which is typically constitutive and widely expressed in all cells.      
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The experimental setup for this investigation used Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) as a housekeeping gene. GAPDH catalyzes the sixth step of 
glycolysis and is therefore constantly expressed at high levels among most tissues.  
 
3.2.4   (Immuno-) Histochemistry 
3.2.4.1   Fixation and slicing 
Prostate tissue samples, originating from human, rat or mouse were fixed in Bouin solution 
(picric acid, acetic acid and formaldehyde) for 24 hours, followed by an ascending alcohol 
series for dehydration. Tissues were embedded in paraffin and allowed to harden completely 
before slicing. Using a RM2255 microtome (Leica, Wetzlar, Germany), slicing thickness was 
set to 5µm.   
 
In addition, previously seeded human prostate interstitial cells were equally fixed with Bouin 
solution. After a short-term incubation for roughly 15 min, Bouin was washed off with pure 
PBS.   
 
3.2.4.2   Azan trichrome stain 
Trichrome stains are highly approved to analyze the general histology of the investigated 
tissue. For the purpose of this study, the Azan stain after Heidenhain was performed, resulting 
in a dark red staining of cell nuclei, whereas collagen is colored in blue.  
 
After deparaffining in descending alcohol series, cell nuclei of investigated rodent and human 
tissue sections were stained with acetocarmine solution at 56 °C for no longer than 15 min, 
under visual control. Phosphotungstic acid binds the dye to the tissue, followed by a second 
step of staining with aniline blue, which marks collagen fibers. For long-term storage, tissue 
sections were dehydrated in isopropanol (and xylene) and finally embedded in mounting 
medium (Eukitt; Fluka, Buchs, Switzerland), protected by Automat Star coverslips 
(Engelbrecht, Edermünde, Germany).  
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3.2.4.3   Immunostaining 
Paraffin-embedded prostate tissue sections from human, rat and mouse were investigated by 
immune reactive staining with a special focus on smooth muscle cells. At first, sections were 
deparaffinized in descending alcohol series, including a step of incubation in 1.2% H2O2 
(dissolved in methanol) to block endogenous peroxidase activity. Primary antibodies for α 
smooth muscle actin (SMA, mouse monoclonal, 1:1000; Sigma-Aldrich, Steinheim, 
Germany), PKG I (rabbit polyclonal, 1:1000, Enzo Life Sciences, Lörrach, Germany) and 
PDE5 (rabbit polyclonal, 1:1000; gift from Laurinda Jaffe, University of Connecticut Health 
Center, Farmington, USA) were diluted in PBS with 0.2% BSA and 0.1% sodium azide and 
incubated at 4 °C overnight to ensure a slow penetration of the antibody into the tissue. Slides 
were transferred to humidity chambers for overnight incubation. Sections without primary 
antibodies served as negative control.  
 
The following day, sections were washed several times in PBS before horseradish peroxidase- 
labeled polymer (DAKO, Hamburg, Germany) was added to each section at RT for 30 min. 
After washing with PBS and 0.1M PB, peroxidase activity was detected by DAB. The 
reaction was initiated by nickel-glucose oxidase amplification and stopped under visual 
control. For the purpose of storage, all sections were dehydrated by ascending alcohol series 
(and xylene) and mounted in Eukitt® Quick-hardening mounting medium (Merck, Darmstadt, 
Germany), protected by Automat Star coverslips. 
 
In addition, immunofluorescence double staining from the same paraffin-embedded tissue 
sections were performed to co-localize two proteins of interest within identic smooth muscle 
cells. The procedure starts again by deparaffinization in descending alcohol series, including 
the incubation in 1.2% H2O2. But after washing in PBS, sections needed to be transferred into 
2% normal goat serum for 1 hour at RT to block unspecific binding sites. Primary antibodies 
for SMA (1:1000) and PDE5 (1:1000) were diluted in PBS with 0.2% BSA and 0.1% sodium 
azide and applied to tissue sections for overnight incubation in humidity chambers at 4 °C. 
Sections without primary antibodies served as negative control. 
 
After a short washing step in PBS the following day, sections were incubated with 
fluorescence-labeled secondary antibodies (Cy3 anti-rabbit IgG, 1:500; Jackson 
ImmunoResearch, West Grove, USA respectively Alexa Fluor 488 anti-mouse IgG, 1:500; 
Thermo Fisher Scientific, Waltham, USA) together with 4′,6-Diamidine-2-phenylindol 
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(DAPI, 1:1250; Merck, Darmstadt, Germany) for 1 hour at RT. Including this step, all 
following steps were performed in darkness to avoid a loss of fluorescence caused by UV 
from daylight. Staining procedure ends by washing of the tissue sections in PBS, followed by 
mounting under coverslips with buffered glycerol for long-term storage at 4 °C.  
 
Apart from prostate tissue sections, immunostaining of cultured human prostatic interstitial 
cells was performed by using a DAB Kit (DAKO, EnVision+System, Peroxidase, Hamburg, 
Germany) which follows the same principles as described earlier. Bouin-fixated cells were 
treated with 0.3% triton x-100 (Merck, Darmstadt, Germany) for 5 min at RT to permeabilize 
them. After short washing of each well with PBS, DAB detection was proceeded according to 
manufacturer's instructions, using primary antibodies for SMA (1:1000), PKG I (1:1000) and 
PDE5 (1:1000). DAB reaction was stopped with water under visual control. Cell nuclei were 
counterstained with hematoxylin (Merck, Darmstadt, Germany) for 10 sec and washed off 
with warm tap water. For short-term storage, cold water was added to each well, sealed by 
parafilm (Bemis NA, Neenah, USA) and transferred to stock at 4 °C.  
 
Conventional light and fluorescence microscopy served for documentation of all performed 
stainings using an Axioplan 2 imaging microscope and Axiovision LE software (Zeiss, 
Munich, Germany). 
 
3.2.5   CLARITY 
CLARITY which is an abbreviation for Clear lipid-exchanged acrylamide-hybridized rigid 
imaging/immunostaining/in situ hybridization-compatible tissue-hydrogel, features an 
improvement of common histological techniques by generating three-dimensional (3D) 
images of whole tissues. The principle of this technique is to conserve biologic tissue by 
transforming it into a translucent hydrogel-tissue hybrid. Biomolecules were mounted in a 
hydrogel matrix to preserve their structural framework before unattached lipids will be 
washed away. Since this technique was developed for clearance of brain tissue, no protocol 
for prostate tissue of any species was available and had to adapt from instructions described 
by Chung and Deisseroth (2013).  
 
The protocol was preceded with prostate tissue samples dissected from rodent ventral lobes or 
human prostate tissue, collected mostly periurethral.  
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Tissue sections of approximately 1 mm3 in size were fixed in 4% paraformaldehyde for 24 
hours at 4 °C. To form a hydrogel mesh with the prostate tissue, incubation of hydrogel 
solution (Tab.4) for 24 hours at 4 °C was followed by its polymerization at 37 °C for 3 hours. 
Remaining hydrogel excess was carefully removed. In a subsequent step, tissue samples were 
incubated in clearing solution (Tab.4) for a minimum of 5 days under visual control to wash 
out most lipids. Removal of lipid components is crucial to avoid light scattering for optimal 
tissue opacity.  
 
 
Hydrogel solution components Final concentration 
Acrylamide 4% 
Bisacrylamide 0.05% 
2,2′-Azobis(2-methylpropionamidine)dihydrochloride  0.25% 
 
Clearing solution components Final concentration 
Sodium dodecyl sulfate (SDS) 10% 
Boric acid 200 mM 
 
Extensive washing steps with 0.1% PBS-Triton were performed before and after adding 
primary antibodies, targeting SMA (1:100), PKG I (1:100), PDE5 (1:100), calponin-1 (rabbit 
monoclonal, 1:100; Epitomics, California, USA), Ki67 (1:100, rabbit polyclonal, Novocastra, 
Newcastle, UK) as well as α-tubulin (mouse monoclonal, 1:100, Sigma-Aldrich, Steinheim, 
Germany) and fluorescence-labeled secondary antibodies (Cy3 anti-rabbit IgG,1:200 and/or 
Alexa Fluor 488 anti-mouse IgG, 1:200). All antibodies (primary and secondary) were diluted 
in 0.1% PBS-Triton and incubated for at least 5 days at RT. Stainings were performed either 
as single antibody staining or double antibody staining in combination with SMA. In addition, 
staining with DAPI (1:400) allowed to distinguish between glandular epithelium and stromal 
smooth muscle cells.  
 
Further 24 hours of tissue washing steps with 0.1% PBS-Triton were executed before the 
tissue was transferred into a refractory index matching solution (RIMS, Tab.5) for 24 hours at 
RT. RIMS buffer optically enhances clearance caused by closely approximated refractory 
indexes of the translucent sample and its embedding solution, which in turn facilitates light to 
pass through with neither refraction nor reflection.  
 
 
                Tab.4: Hydrogel and buffer composition for tissue clearing.                                                               
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Refractory index matching solution components Final concentration 
Histodenz 88% 
Tween-20  0.1% 
Sodium azide 0.01% 
 
Finally, samples were mounted in RIMS buffer on common slides. Because sample thickness 
could easily reach 2 mm, the gap between slide and coverslip was bridged by a ring of blue 
tack (Bostik, Wauwatosa, USA).    
 
Documentation of all samples was performed on a LSM 710 Confocal Laser Scanning 
Microscope (Observer.Z1, Zeiss, Munich, Germany), capturing z-stacks with a slice distances 
between 1.5 to 5 μm.  
 
Z-stacks were reconstructed using the open source program ImageJ 1.50e (public domain 
software, NIH, USA, download at http://imagej.hih.gov/ij). The integrated program tool “3D 
projects” provides a simple setup for interpolated 3D reconstructions and offers the 
opportunity for automatic contrast enhancement, if necessary.  
 
3.2.6   Time-lapse imaging 
For the purpose of functional investigations, time-lapse imaging was performed in 
combination with transillumination microscopy to visualize relevant drug effects of the 
PDE5-inhibitor sildenafil on smooth muscle cell contractility. The total tissue of the 
periurethral or peripheral aspect of the human prostate respectively, glands and duct of the rat 
ventral lobes were embedded in a collagen suspension to ensure tissue immobilization. 
Collagen was collected from tails of adult rats and suspended in 10x DMEM/F12 (Gibco, 
Invitrogen, Karlsruhe, Germany), together with 0.1% glacial acetic acid, 0.5 M sodium 
hydroxide and 1 M HEPES. Prostate samples were placed inside the viscous collagen solution 
and mounted at the bottom of a Delta T dish (Bioptechs, Buttler, USA). At 37 °C collagen 
was polymerized and covered by 1 ml MEM for optimal tissue supply.      
 
Time-stack recording was performed using a BX50WI transillumination microscope 
(Olympus, Tokio, Japan) equipped with UMPlan Fl 10x/0,5 W and UMPlanFl 20x/0,5 W 
objectives that were attached to a Till-Imago QE CCD camera (Photonics, Gräfelfing, 
Germany). Camera input was recorded by TillVision software (Version 4.0, Photonics). 
                Tab.5: RIMS buffer composition for optical clearance enhancement. 
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Pictures were taken automatically every 2 sec to produce virtual time-stacks. The temperature 
was set constantly to 34 °C during the whole recording time. 
 
Experimental set up always included the following drugs and durations. During the first 30 
min, spontaneous contractility was observed which and used as positive control, followed by 
15 min treatment with the PDE5 inhibitor sildenafil (5 µM, Pfizer, New York, USA). To 
proof for tissue vitality, any response to noradrenaline (10 µM, Sigma-Aldrich, Steinheim, 
Germany) a neurotransmitter of α1-adrenoceptor from the prostatic autonomic nervous system 
was recorded for additional 15 min. All investigated substances were directly dripped into 
MEM. In a final step, histological determination of all observed tissues was confirmed by 
paraffin-embedded azan stainings.  
 
Digital time-stack processing used ImageJ 1.50e (public domain software, NIH, USA, 
download at http://imagej.hih.gov/ij) to visualize smooth muscle cell contractions. Regions of 
interest were defined for contractile areas and followed over time. The built-in tool “Reslice” 
translated all contractions into visible peaks on a fixed timescale. Contrast enhancement was 
adjusted if necessary to improve the final outcome. Contraction frequency could then easily 
calculated as the number of peaks over time. First 10 min of spontaneous contractions, 
respectively first 4 min after drug addition were taken as residence time and excluded from 
calculations. Sample recordings without any visible drug response were excluded from 
statistics. 
 
3.2.7   Western Blot 
Next to immunostaining, the protein level of certain cGMP pathway components was 
additionally analyzed from tissue homogenates of the rat and mouse ventral prostate. Western 
Blot protocol was preceded as described by (Müller et al. 2011)) with only slight 
modifications.  
 
In the first step of protein isolation, rodent prostate tissue was transferred into lysis buffer, 
followed by tissue break down with the help of a SonoPlus mini 20 ultrasonic homogenizer 
(Setting: pulse 0,005s, time 1min, Am 90%, Bandelin, Berlin, Germany). Since prostate tissue 
reveals high protease activity, protein isolation was performed on ice. Cell debris was 
homogenized in lysis buffer (Tab.6) and centrifuged at 3000 x g for 8 min at 4 °C. The 
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remaining pellet was discarded. The supernatant, containing total isolated proteins was frozen 
with liquid nitrogen and stored at -80 °C.  
 
Lysis buffer components  Final concentration 
Tris/HCL (pH 7.5) 50 mM 
Sodium chloride 150 mM 
EDTA 5 mM 
Triton X-100 1% (w/v) 
Sodium deoxycholic acid 5% (w/v) 
Phenylmethanesulfonyl fluoride (PMSF) 2 mM 
Aprotinin 1 mM 
Leupeptin  1 mM 
 
For measurement of total protein concentration, a Bradford protein assay (Bio-Rad, Munich, 
Germany) was used. Coomassie Brilliant Blue G-250 dye binds to proteins which in turn shift 
its absorbance maximum for an acidic solution from 465 nm to 595 nm. Detection of final 
protein concentration was measured at 595 nm by a microplate reader. Bovine serum albumin 
(3 to 18 µg/µl) served as standardized control.  
 
Equal amounts of protein samples were transferred to 3x SDS gel loading buffer (Tab.7) and 
denatured at 104 °C for 2 min. SDS binds to the hydrophobic regions of proteins which turn 
the protein charge into a constant negative state and enables the separation of proteins 
according to their molecular weight during gel electrophoresis. SDS polyacrylamide gels 
(10%) run in a SE 600 vertical electrophoresis system (Hoefer Scientific Instruments, MA, 
USA), firstly with 13 W for 1 hour to concentrate all proteins within each sample and 
secondly with 17 W for 2 hours to separate protein samples. The protein ladder wide range 
(Sigma-Aldrich, Steinheim, Germany) and/or Page ruler™ Plus (Thermo Fisher Scientific, 
Waltham, USA) were used to estimate protein length.  
 
 
3x gel loading buffer components Final concentration 
Tris 375 mM 
Dithiothreitol (DTT) 200 mM 
Sodium dodecyl sulfate (SDS) 15% (w/v) 
Glycerin 20% (v/v) 
Bromphenol blue 0.6 mg/ml 
 
 
                            Tab.6: Lysis buffer for cell break down.                                                                                    
                                   Tab.7: Gel and buffer composition for gel electrophoresis.                                              
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Gel running buffer components Final concentration 
Tris 25 mM 
Glycine 192 mM 
Sodium dodecyl sulfate (SDS) 0.1% (w/v) 
 
Resolving gel buffer components Final concentration 
Tris 375 mM 
Sodium dodecyl sulfate (SDS) 0.1% (w/v) 
 
Resolving gel (10%) components Final concentration 
4x Resolving gel buffer (pH 8.5) 15 ml 
Acrylamide solution (30%) 20 ml 
Distilled water 24,7 ml 
Ammonium persulfate (10%)  0.25 ml 
Temed 0.05 ml 
Total volume 60 ml 
 
Stacking gel buffer components Final concentration 
Tris 500 mM 
Sodium dodecyl sulfate (SDS) 0.1% (w/v) 
 
 
Stacking gel components Final concentration 
4x Stacking gel buffer (pH 6.8) 5 ml 
Acrylamide solution (30%) 2.6 ml 
Distilled water  12.275 ml 
Ammonium persulfate (10%)  0.1 ml 
Temed 0.025 ml 
Total volume 60 ml 
 
Separated proteins were transferred to Amersham™ Hyperbond™ - ECL nitrocellulose 
membranes (GE Healthcare, Freiburg, Germany) at 27 volts overnight. Next day incubation 
with Ponceau-S (Merck, Munich, Germany) for 10 min at RT was used to reveal the efficacy 
of protein blotting which was scanned for documentation. Membranes were subsequently 
incubated in blocking reagent (Roche, Mannheim, Germany) for 2 hours at RT.  
 
 
Blotting buffer components Final concentration 
Tris 100 mM 
Glycine 193 mM 
 
                                Tab.8: Buffer composition for nitrocellulose transfer.                                                         
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TBS-T components Final concentration 
Tris 20 mM 
Sodium chloride 137 mM 
Tween 20 0.05% (v/v) 
 
After a few washing steps with distilled water, immunoblotting started using the following 
primary antibodies: α smooth muscle actin (SMA, mouse monoclonal, 1:1000; Sigma-
Aldrich, Steinheim, Germany), PKG I (rabbit polyclonal, 1:1000, Enzo Life Sciences, 
Lörrach, Germany), PDE5 (rabbit polyclonal, 1:1000; gift from Laurinda Jaffe, University of 
Connecticut Health Center, Farmington, USA), sGC (rabbit polyclonal, 1:5000, CAYMAN, 
Ann Arbor, USA) and vinculin (mouse monoclonal, 1:6000, Sigma-Aldrich, Steinheim, 
Germany). Incubation took 1 hour followed by short washing with TBS-T (Tab.6), before 
horseradish peroxidase-conjugated secondary antibodies (goat-anti-mouse respectively goat-
anti-rabbit IgG, 1:2000, Pierce, Bonn, Germany) were applied. All antibodies were diluted in 
antibody incubation buffer (90% TBS-T, 10% blocking buffer, 0.005% Thimerosal).  
 
Protein signals were detected by chemiluminescence, using Amersham™ enhanced 
chemiluminescence reagent (GE Healthcare, Freiburg, Germany). Signal illumination was 
finally captured on x-ray film (Fuji, Tokio, Japan).      
 
Membrane stripping followed directly after protein signal detection, to wash off any 
remaining antibodies. This procedure always started with the incubation in 5% skimmed-milk 
(Roth, Karlsruhe, Germany) which protects proteins from the subsequent washing step with 
0.5 M sodium chloride/ 0.5 M  acetic acid. After washing with distilled water and 1.5 M Tris 
membranes were either dried completely for long-term storage at 4 °C or reused for 
incubation with further primary antibodies following the previously described protocol.    
 
For detailed comparisons of individual protein levels within each sample densitometric 
quantification was performed. Band intensity values were measured by ImageJ 1.50e (public 
domain software, NIH, USA, download at http://imagej.hih.gov/ij) and normalized to those of 
vinculin.   
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3.2.8   Statistical analysis 
All final graphs and statistics were performed with the statistics program GraphPad Prism 
(version 6.02 for Windows, GraphPad Software, La Jolla, California, USA, 
www.graphpad.com). In detail, determination for normally distributed data was achieved with 
the Kolmogorov-Smirnov test. Data sets were analyzed using a one-tailed t-test in case of 
normal distribution, otherwise Mann-Whitney U test was performed. 
 
For significance analysis of data produced by time-lapse imaging, only vital samples were 
included in statistics. Sample vitality was confirmed by any visible response to noradrenaline 
at the end of each time-lapse experiment. Data pairing was assumed for comparisons between 
calculated contraction frequencies before and after sildenafil addition. Values from all other 
investigations were treated as unpaired data.  
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4 Results 
 
4.1   Localization of SMCs in acini and ducts of the rat ventral prostate 
Prostatic ventral lobes in rats consist of numerous prostatic acini that drain into the urethra by 
elongated prostatic ducts (Fig.7A). Secretion of the acini is mediated by glandular epithelium. 
Acini and ducts are loosely embedded in stromal connective tissue, interspersed with blood 
vessels (Fig.7B). Both prostatic structures are encircled with layers of SMCs, shown by 
immunostainings for smooth muscle actin (SMA). Interestingly, numerous layers of SMCs 
surround the proximal ducts, while prostate acini (Fig.7C) are encircled with only a thin layer 
of SMCs.  
 
Independently of their individual localization within the prostate ventral lobe, all smooth 
muscle cells were found to express PDE5 and PKG I which represent two well-known 
enzymes, involved in the cGMP pathway for smooth muscle contractility (Fig.7D, E). 
Staining from serial cuttings therefore, offers the opportunity to compare the expression of 
several proteins within equal cellular structures. In contrast to SMCs, epithelial cells of 
prostatic ducts and glands lack any positive immunostaining for PDE5 and PKG I.  
 
4.2   The architecture of prostatic SMCs in rat and mouse 
4.2.1    3D reconstruction of rat prostate tissue 
The development of a novel CLARITY protocol which is adapted for clearance of prostate 
tissue provided a totally new perspective of the anatomic architecture of prostatic SMCs. For 
the first time, the very tight arrangement of those SMCs could follow simultaneously over 
several anatomically intact prostate glands.  
 
It was shown that SMCs surround prostatic acini neither evenly nor totally chaotic. In fact, 
peri-glandular SMCs rather form large bandage-like structures that tightly enclose the 
complete prostate gland, interrupted by roundish areas without SMCs (Fig.8A). SMCs follow 
various directions and partly overlap each other (indicated with white arrowheads). Larger 
areas that lack SMCs were commonly found at the tips and branchpoints of the acini (Fig.8A, 
indicated with white asterisks). 
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Fig.7: General histology of the rat ventral prostate 
(serial sections). 
A-B: Azan stain of the rat ventral prostate in 
transversal orientation exhibited numerous glands (g) 
which drain into the urethra by elongated prostatic 
ducts (d). C: Immunostaining for smooth muscle actin 
(SMA) revealed numerous layers of SMCs around 
prostatic ducts in contrast to the thin SMC layer 
around glands. Vascular SMCs were visible in vessels 
(v) of the interstitial zone. D: Serial sections 
demonstrated co-expression of PKG I within prostatic 
SMCs. E: PDE5 expression was found co-localized 
also with SMA and PKG I in prostatic SMCs of serial 
sections. Scale bar (A): 200 µm, scale bars (B-E): 50 
µm. 
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Expression of calponin-1, a protein crucial for smooth muscle contractility, was investigated 
in addition (Fig.8B). Although calponin expression was found to be less intense compared to 
smooth muscle actin in the rat ventral prostate, the same peri-glandular SMC localization was 
confirmed, highlighting elongated clusters of SMCs either overlapping each other (Fig.8B, 
indicated with arrowheads) or forming empty areas (Fig.8B, indicated with asterisks).  
 
 
 
 
 
Fig.8: Virtual reconstructions of rat prostate glands. 
A: Expression of SMA illustrates SMC architecture, forming bandage-like SMCs that overlap each other 
(arrowheads) or exhibit empty areas (asterisks). B: Expression of calponin confirmed SMC arrangement, which 
tightly encloses all prostatic acini. C: PKG I was found to be expressed without any distinct orientation around 
the whole prostate glands. D: Similar to PKG I localization, PDE5 was expression tightly around all prostatic 
acini. Scale bars (A-C): 75 µm, scale bar (D): 20 µm. 
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Similar to SMC location, PKG I expression was also found in a peri-glandular manner around 
the whole prostate glands but without any distinct orientation (Fig.8C). The same location 
pattern was observed in case of PDE5 expression in rat ventral prostate tissues (Fig.8D).    
 
4.2.2    3D reconstruction of mouse prostate tissue 
Acini of the mouse ventral prostate showed a similar organization of peri-glandular SMCs 
compared to rat. Tightly encircling all prostatic acini, SMCs form bandage-like structures 
which partially overlap or leave empty areas (Fig.9A-C).  
 
Interestingly, co-localization of calponin and smooth muscle actin revealed structural 
differences between both SMC markers (Fig.9A-B). Most acini were found to express both 
SMC markers, except of only a few glandular parts which lack expression of either one of 
them (Fig. 9A-B, indicated with white arrows). Furthermore, smooth muscle actin expression 
seems to be enriched in certain cells and therefore highlights individual bandage-like SMC 
structures, while calponin was expressed equally through all glandular SMCs.  
 
PDE5 expression from double staining with smooth muscle actin was found peri-glandularly 
but without any distinct orientation (Fig.9C, D). This finding confirmed the expression pattern 
already described for rat prostate glands (see Fig.8A). In addition, weak expression of PDE5 
was also visible in SMCs of the vasculature (Fig.9D).  
 
Although α-tubulin itself is a globular protein, forming microtubule cytoskeleton in 
eukaryotic cells, an antibody for α-tubulin could be used for reconstruction of the prostatic 
innervation network (Fig.9E). A dense network of autonomic nerve fibers was clearly visible, 
innervating the epithelium-enclosing SMC layer of the mouse prostate. Counterstaining with 
DAPI helped to reflect the general shape of the prostatic acini.  
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Fig.9: Virtual reconstruction of the mouse prostate 
glands. 
A-B: Double staining of SMA (green) together with 
calponin (red) showed equal expression pattern of 
both SMC markers except few glandular parts 
(arrows). C-D: Double staining showed PDE5 (red) 
to be expressed tightly around prostatic acini and 
vasculature (v) within prostatic SMCs that were 
marked by SMA (green). E: Visualization of SMC 
innervation by α-tubulin, while counterstaining with 
DAPI outlined the general dimensions of the distal 
acini. Scale bars (A-E): 75 µm. 
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4.3   Prostatic vasculature in rats 
In order to investigate all structures of the rat ventral prostate that contain SMCs, the prostatic 
vasculature was investigated in addition to those SMCs located around acini and ducts. 
Numerous blood vessels supply the rat ventral prostate which consists of three major layers. 
The tunica intima forms the inner layer by endothelial cells, whereas the outer layer is known 
as tunica adventitia that contains connective tissue and nerve fibers. Between these two layers, 
an intermediate layer called tunica media is located. It is built up from SMCs and connective 
tissue. SMCs of the tunica media regulate blood flow by controlling the caliber of the blood 
vessels (Prins and Lindgren 2015).  
 
 
 
 
 
 
Fig.10: PDE5 expression within the rat prostatic vasculature. 
A-B: Double staining on rat ventral prostate sections revealed PDE5 expression in SMCs of the vasculature (v) 
marked by SMA (green). PDE5 (red) expression in glandular SMCs (g) served as positive control. C: Three-
dimensional orientation of vascular SMCs was visualized by CLARITY. SMA staining revealed numerous 
vascular branchpoints. Higher magnification demonstrated the circular orientation of SMCs in prostatic vessels 
(arrowheads). D: PDE5 expression in three-dimensional reconstructions of the rat prostate confirmed its 
localization within vascular SMC with circular orientation. Scale bars (A-B): 25 µm, scale bars (C-D): 75 µm. 
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Co-expression of PDE5 together with smooth muscle actin unequivocally revealed PDE5 to 
be expressed only in SMCs (Fig.10A-B). Localization of PDE5 expression within vascular 
SMCs was confirmed by CLARITY (Fig.10C-D) which gives an impressive insight of the 
three-dimensional architecture of the prostatic vasculature. The circular orientation of 
vascular SMCs was clearly visible (Fig10C-D, indicated with white arrowheads) as well as 
several branchpoints.   
 
4.4   SMCs of the human prostate 
Tissue samples from biopsies donated by patients that underwent radical prostatectomy or 
transurethral resection were histologically investigated using classical AZAN and 
immunostaining. Comparisons to rodent prostate histology focused on prostatic smooth 
muscle cells and revealed some differences between those species. Although in all 
investigated species SMCs were found to be present in the stroma between prostatic glands 
and ducts, SMCs of the rodent prostate tightly enclose glands and ducts (see Fig.7C) whereas 
SMCs of the human prostate were found across the entire interstitial zone (Fig.11B, indicated 
with arrows) alternating with connective tissue (Fig.11A). Different to the rodent prostate in 
which prostate glands were loosely connected to each other, human prostate glands gain 
stability by a massive prevalence of connective tissue and SMCs (Fig.11A) throughout the 
prostatic stroma. 
 
Proximal ducts in rodents were easily distinguishable from glands according to several SMC 
layers that surround the epithelial layer of the prostatic ducts, while glands were found to be 
encircled just by a thin SMC layer. In men, prostatic ducts were identified due to their 
elongated shape compared to prostate glands, often surrounded by numerous SMCs. 
However, a systematic analysis that helps to clearly distinguish between ductal and glandular 
SMCs would be of importance.  
 
Within the human prostatic stroma, immunostaining for PDE5 showed expression of this 
cGMP-degrading enzyme only in SMCs (Fig.11C) while glandular epithelium cells lack any 
positive staining. According to previous findings in rat prostate, the cGMP target enzyme 
PKG I was also localized exclusively in SMCs of the human prostate (Fig.11D).  
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4.5   The 3D architecture of SMCs in the human prostate 
For the visualization of the SMC arrangement between individual prostatic glands, CLARITY 
was performed using human biopsy samples. Tissue samples were labeled with an antibody 
for smooth muscle actin together with DAPI. The distinct organization of interstitial SMCs 
was easily observable. SMCs were not only found directly surrounding the glandular 
epithelium but were also visible in all parts of the interstitial tissue (Fig.12A), alternating with 
connective tissue and extend between prostate glands (see Fig.11A). 
 
In addition, cellular localization of PDE5 expression was investigated by co-localization of 
smooth muscle actin and PDE5 (Fig.12B-E). Immunofluorescence staining on paraffin- 
embedded tissue nicely revealed the expression of PDE5 within interstitial SMCs (Fig.12B-
C), determined by smooth muscle actin.     
 
Fig.11: General histology of the human prostate.  
A: SMCs were located in all parts of the prostatic interstitial zone and massively interspersed by connective 
tissue (blue). Elongated ducts (d) were visible in close proximity to prostate glands (g). B: Immunostaining for 
SMA confirmed SMCs (arrows) to be located across the entire interstitial zone. C: PDE5 expression was 
limited to SMCs only. D: Besides interstitial SMCs, PKG I was localized also within SMCs of the vasculature 
(v). Scale bars (A-D): 100 µm. 
Results 
51 
 
To gain a more vivid impression of PDE5-expressing SMCs within the human prostate, 
CLARITY was performed as double staining with antibodies for PDE5 and smooth muscle 
actin. The PDE5 expression followed exactly the localization of elongated SMCs which either 
surround prostatic glands or stretch further through the stroma (Fig.12D-E). Interestingly, 
interstitial SMCs in close proximity to glands were commonly found in a longitudinal 
orientation, while those SMCs distal from glands were also oriented transversally of multiple 
directions (Fig.12D).  
 
 
 
 
 
 
Fig.12: Visualization of human prostatic SMCs.  
A:In the CLARITY approach from human prostate biopsies SMA (green) and DAPI (blue) were used to 
visualize SMCs that extend in all parts of the interstitial zone between prostatic glands (g). B-C: Double 
staining on paraffin-embedded human prostate biopsies revealed PDE5 (red) expression in interstitial SMCs 
which were localized by SMA (green) staining. D-E: CLARITY-based double staining visualized the three-
dimensional architecture of PDE5 (red) -expressing human prostatic SMCs visualized by SMA (green). Scale 
bars (A, F, G): 75 µm, scale bars (B, C): 25 µm. 
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4.6   Vasculature of the human prostate 
In paraffin embedded human tissue samples SMCs of the tunica media could be detected by 
positive immunostaining for smooth muscle actin (Fig.13A). Co-localization with PDE5 
confirmed expression in vascular smooth muscle cells (Fig.13B) as already described in case 
of rat prostatic blood vessels (see Fig.10A-D) with exception of few interfering artifacts, 
presumably erythrocytes.  
 
In a second approach, the differentiation status of vascular SMCs in comparison to interstitial 
SMCs was tested. CLARITY double staining for calponin (to detect more differentiated 
SMCs) and SMA (to visualize smooth muscle cells in general) revealed SMA expression in 
vascular smooth muscle cells (Fig.13C) but lacked expression of calponin within the same 
vessels (Fig.13D). Interstitial SMCs, however regularly showed co-expression of smooth 
muscle actin and calponin (indicated with white arrows). This in turn, suggests a more 
differentiated phenotype of interstitial SMCs compared to vascular SMCs (Fig.13C-E).  
 
 
 
 
 
 
 
Fig.13: SMCs of the human prostatic vasculature. 
A-B: Double staining on paraffin-embedded human biopsies of the prostate exhibited co-localization of PDE5 
(red) within SMCs of the prostatic vasculature (v) labeled with antibody for SMA (green). C-E: Large vessel (v) 
of the human prostate that was cleared and stained with our CLARITY approach showed calponin (red) 
expression (marker for differentiated SMCs) exclusively in interstitial SMCs (arrows). Both, interstitial and 
vascular SMCs were capable of labeling with SMA, a general SMC marker. Scale bars (A-B): 10 µm, scale bars 
(C-E): 25 µm.   
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4.7   Functional analysis 
4.7.1   Contractility of rat prostate acini 
In order to investigate the functional mechanism of PDE5 action in the prostate, isolated acini 
of the rat ventral prostate were investigated using time-lapse imaging on transillumination 
microscopy. As described earlier (see Fig.8A) prostate acini in rat were found tightly 
encircled by SMCs. Spontaneous contractions of glandular musculature were visible along the 
wall of acini (Fig.14A) and exhibited a slightly irregular pattern (Fig.14B). However, the 
potency of contractions and contractile pattern did not differ (data not shown) among various 
parts of the gland. Time-lapse images of wall movements were treated as time stacks and 
translated into little peaks (Fig.14B, indicated with arrows) to follow them over time. 
Treatment with the PDE5 inhibitor sildenafil immediately resulted in a reduction of the 
contractile frequency (Fig.14B). Subsequent addition of noradrenaline confirmed tissue 
viability (not shown). Drug effect was proven to be statistically significant by analyzing a 
total number of 8 individual animals (Fig.14C).    
 
 
 
 
 
 
 
Fig.14: Analysis of contractility of rat prostate glands.  
A: Freeze frame of single glands dissected from the rat ventral prostate. Blue line indicates the region of interest 
(ROI) from which wall movements were depicted. Scale bar (A): 100 µm. B: Time stack originating from ROI in 
(A) with spontaneous contractions were visible as twitches (arrows) and stopped completely after addition of 
sildenafil. C: Paired, one-tailed t-test proved a highly significant reduction of the contractile frequency after 
addition of sildenafil (n=8, **p<0.01).  
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4.7.2   Contraction of rat prostatic ducts 
Ducts of the rat ventral prostate which directly drain into the urethra were investigated 
regarding their response to the PDE5 inhibitor sildenafil. In contrast to acini, proximal 
prostatic ducts are surrounded by several layers of SMCs which is why ducts were analyzed 
separately to acini. For comparison of both structures, time-lapse imaging of the prostatic 
ducts used the same experimental set up as previously established for contractile recordings of 
prostatic acini.  
 
Time-lapse imaging revealed no spontaneous contractions on prostatic ducts at any time 
(Fig.15C). Also, no detectable response was visible after treatment with sildenafil. However, 
the addition of noradrenaline to mimic sympathetic stimulation instantly caused a dramatic 
contraction of the whole duct (Fig15A-B).    
 
 
 
 
 
 
 
 
 
Fig.15: Analysis of contractions of rat prostatic ducts. 
A: Freeze frame of untreated proximal duct from the rat ventral prostate. Blue line indicates the region of 
interest (ROI) from which movements of the interstitial zone were depicted. B: Freeze frame from identic duct 
as shown in (A). Addition of noradrenaline resulted in a dramatic contraction of the whole duct. Scale bars (A-
B): 75 µm. C: Time stack, originating from the ROI visible in (A) and (B) as a blue line, showed no 
spontaneous contractions, neither under untreated conditions nor after addition of sildenafil. Addition of 
noradrenaline immediately caused a striking reduction of the ductal diameter.  
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4.7.3   Contractility of the human prostate 
Comparison of human and rodent prostate anatomy shows obvious histological differences. 
Despite this, it should be tested whether PDE5 action in prostatic SMCs of both species was 
comparable. Therefore tissue sample from donors suffering of BPH or prostate cancer were 
analyzed for contractility. To ensure transillumination, tissue sections were sliced as thin as 
possible by hand in regions with visible prostate gland proportion.   
 
Fig.16: Analysis of contractility of human 
prostate tissue. 
A: Freeze frame of human prostate tissue from a 
BPH patient. Blue line indicates the region of 
interest (ROI) which was used for time stack 
analysis. B: Azan stained section from the tissue 
shown in (A) after contractility studies. Interstitial 
SMCs are stained in red. Scale bars (A-B): 75 µm. 
C: Time stack originating from ROI in (A) 
visualized slow, spontaneous contractions (arrows) 
that were reduced (or even abolished in this 
experiment) by addition of sildenafil. D: Paired, 
one-tailed t-test confirmed highly significant 
reduction of the contractile frequency after addition 
of sildenafil (n=6, *p<0.05).  
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Slow contractions occurred spontaneously in form of partial movements of the interstitial 
tissue. Contractility was visible in close proximity to prostate glands with a slightly irregular 
pattern. Regions with highest contractile activity were used to capture (Fig.16A) and translate 
tissue movements into countable peaks (Fig.16C).   
 
Treatment with the PDE5 inhibitor sildenafil immediately reduced spontaneous contractions 
or even abolished those movements completely. With a total number of 6 cases, contractile 
reduction by sildenafil was statistically confirmed (Fig.16D).  
 
Treatment with noradrenaline at the end of each experiment served as vitality control. All 
investigated human tissues were subsequently embedded in paraffin and stained with AZAN 
(Fig.16B) to visualize contractile structures.      
 
4.7.4   Vascular contractions 
In rats, arteries were regularly found directly attached to those proximal ducts of the ventral 
lobes that enter the urethra at its ventral aspect. Single blood vessels were dissected (Fig.17A) 
in order to observe any contractile response to sildenafil and noradrenaline. Due to the 
mechanism of normal blood vessel function, spontaneous contractions were not found for 
vascular SMCs as expected and therefore induced by noradrenaline.  
 
 
 
 
 
Fig.17: Analysis of contractions of prostatic vasculature in rats.  
All freeze frames (A-C) represent different time points out of one single experiment. A: Large blood vessel 
originating from the proximal aspect of the rat ventral prostate without any treatment. B: Addition of 
noradrenaline caused circular compression of the vascular SMCs that reduced the vessel diameter (white 
arrows). C: Re-expanded vascular diameter after treatment with sildenafil. Scale bars (A-C): 50 µm. 
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In some cases, only short parts along the investigated vessels showed circular compression of 
the vascular musculature after noradrenaline addition (Fig.17B). This in turn, leads to a 
dramatic reduction of the vessel diameter in those arterial parts.  
 
Sildenafil-treated vessels than reestablished their arterial diameter with a final dimension 
comparable to the untreated situation at the beginning of the experiment (Fig.17A, C).  
 
4.8   Hormonal influences on prostatic musculature 
4.8.1   Postnatal development of SMC architecture in rats  
Development and homeostasis of the prostate are highly androgen-dependent, similar to other 
organs of the male genital tract like testis or epididymis. Dynamics of serum testosterone 
levels are comparable in rats and men with very low levels shortly after birth and highest 
adult levels (Picut et al. 2018). Because of this contrasting situation, prostatic SMCs from 
adult rats were compared to those just reaching postnatal day 6 (6d).  
 
In order to identify age-related differences in prostatic SMCs, acini from adult respectively 6d 
old rats were investigated using our three-dimensional CLARITY approach. Apart from the 
smaller size with fewer branches of the developing postnatal rat prostate, further histological 
changes were observed. The focus of this investigation was on age-related changes in the 
expression of smooth muscle actin and PDE5 within peri-glandular SMCs.  
 
In adult rats, peri-glandular SMCs (stained with antibody for smooth muscle actin) were 
found tightly around prostatic acini forming large bandage-like structures (marked with 
arrows) which were disrupted by some empty areas (Fig.18A-B, see also Fig.8A). 
Comparison with the smooth muscle actin staining of the postnatal prostate acinus (6d) 
revealed SMCs to be similarly arranged and oriented (indicated with arrowheads) as observed 
in adult animals (Fig.18C-D). However, explicit differences in case of expression intensity 
were observable. While “bandages” around adult acini were visible as clear compact 
structure, those from postnatal rats showed highest smooth muscle actin expression along the 
edges of the  “bandages” and weakened to the center (Fig.18C-D). This less distinct 
expression of smooth muscle actin in the postnatal prostate coincided with lower PDE5 
expression obtained from identical peri-glandular SMCs. Localization of PDE5 exhibited a 
rather diffuse expression around most postnatal acini (Fig.18E-F) and thus reflected just 
barely the general architecture of peri-glandular SMCs. This contrasted previous described 
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PDE5 expression investigated in adult rats (see Fig.8D) which was localized tightly around 
prostatic acini.    
 
 
Fig.18: Adult vs. postnatal architecture of the rat 
ventral prostate. 
A-B: CLARITY from prostate tissue of adult rats 
stained with antibody for SMA. Higher 
magnification demonstrated the formation of peri-
glandular SMCs in bandage-like structures (arrows), 
disrupted by some muscle-free areas. C-E: 
CLARITY double staining from postnatal prostate 
with antibody for SMA (green, C-D) and PDE5 
(red, E). Orientation and formation of bandage-like 
SMC architecture (arrows) were comparable to 
adult prostate in higher magnification. Scale bars 
(A, C, E): 75 µm, scale bars (B, D): 25 µm. 
Results 
59 
 
4.8.2   Castration-induced androgen deprivation in rats 
To get deeper insights how testosterone influences the cGMP pathway, a testosterone 
deprivation model was used to study possible changes of the rat ventral prostate. In detail, 
testosterone deprivation was ensured by castration of male Wistar rats, followed by treatment 
with defined amounts of testosterone to restore hormone cut-off.  
 
Western blot analysis was used to determine the regulatory effect of increasing testosterone 
levels on the cGMP target protein PKG I (Fig.19). In prostate, highest PKG I level was found 
at vehicle control which represents a total loss of all testosterone resources. Interestingly, a 
correlation of increasing testosterone concentrations together with decreasing PKG I 
expression was clearly visible at the immunoblot. Protein kinase B (PKB) was used as a 
reference for another protein kinase that exhibited no differences in any treatment within the 
prostate.  
 
Protein preparation of skeletal muscles and penis (further androgen-dependent organ of the 
genital tract) served as positive control and showed no differences in the expression of both 
protein kinases at any obtained testosterone treatment. This finding demonstrates the 
regulatory capacity of testosterone on PKG I expression within the rat prostate.    
 
 
 
 
 
 
 
 
Fig.19: PKG I regulation by testosterone deprivation in rats.  
Western Blot analysis of male Wistar rats after hormone cut-off (via castration) followed by artificial testosterone 
restoring. PKG I expression within the prostate decreased by increasing concentration of testosterone with highest 
amounts of PKG I at vehicle control. In penis (androgen-dependent organ of the male reproductive tract) and 
skeletal muscle (androgen-independent tissue) PKG I expression was found unchanged at any given testosterone 
condition. Protein kinase type B (PKB) served as positive control. Expression of PKB was not influenced by 
hormone cut-off or its restoring.   
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4.8.3   Genetically modified mouse models 
4.8.3.1   Aromatase models affecting both, estrogens and androgens 
Testosterone deprivation by castration showed visible regulatory effects on the expression of 
PKG I in the rodent prostate. Next step was to investigate how changes of estrogen potentially 
influence the cGMP pathway. For this purpose two different genetically modified aromatase 
mouse models were investigated, an estrogen-deficient aromatase knockout (ArKO) mouse, 
generated by targeted disruption of the cyp19 gene (Bianco et al. 2006; Fisher et al. 1998) as 
well as an aromatase overexpression (AROM+) mouse, bearing the human ubiquitin C 
promoter/human P450 aromatase fusion gene (Ellem et al. 2009; Li et al. 2001). Aromatase in 
general, is responsible for the conversion of testosterone to estradiol via formation of an 
aromatic A-ring. The aromatase knockout (ArKO) maintain a complete lack of estrogen in 
mice, while serum testosterone levels increase up to 8 times the wild type (WT) level 
(Risbridger et al. 2003). Opposite hormonal serum levels are present in case of an 
overexpression of aromatase (AROM+) in mice which cause dramatically increased estrogen 
production by using up almost all produced testosterone (Li et al. 2001).  
 
In a first step, tissue samples from the prostatic ventral lobe of ArKO, AROM+ and wild type 
mice were evaluated regarding changes in levels of the cGMP target protein PKG I using 
Western blot analysis (Fig.20A). In addition, cGMP-regulating enzymes PDE5 (degrades 
cGMP) and sGC (produces cGMP) were analyzed. Vinculin, a cytoskeletal protein served as a 
loading control and revealed no quantifiable difference between all three mouse groups 
(n=10). 
 
Densitometric analysis revealed a significant increase of PKG I expression in AROM+ mice 
compared to wild type, while PKG I expression in ArKO mice was found to be 
downregulated (Fig.20B). This provides the first evidence for an estrogen-regulated enzyme 
involved in the cGMP pathway within the prostate.  
 
Regarding PDE5, expression of this cGMP-degrading enzyme was found also significantly 
increased in AROM+ mice compared to ArKO mice (Fig.20C).   
 
Despite a slight increase in AROM+ mice, respectively decrease in ArKO mice, comparison 
of sGC expression between all three mouse groups revealed no statistically significant 
differences (Fig.20D).     
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4.8.3.2   Localization of prostate structures showing hormone-induced PKG I regulation 
Paraffin-embedded prostate tissue sections originating from the ventral lobe of ArKO, 
AROM+ and wild type mice were stained immunohistochemically using a PKG I antibody. In 
all 3 groups of mice (n= 24) PKG I expression was clearly visible in vascular SMCs (Fig.21A, 
C, E). Striking differences were found in SMCs surrounding the glandular epithelium. While 
ArKO mice lack almost all peri-glandular PKG I expression, a considerable increase of PKG I 
around prostate glands was found in AROM+ mice compared to wild type.  
 
To check whether the regulatory effect of hormones was simply caused by regulation of the 
number of SMCs, staining of serial sections of all investigated animals were performed using 
a smooth muscle actin antibody. Comparison of all three groups of mice revealed no visible 
difference in the amount of SMCs encircling the prostate glands (Fig.21B, D, F) which 
supports the assumption of a true hormone-dependent regulation of PKG I in prostatic SMCs.   
Fig.20: cGMP-dependent Protein kinase I regulation in the prostate of ArKO, WT and AROM+ mice. 
A: Western Blot analysis of PKG I, PDE5 and sGC from prostate tissue of genetically modified mouse models 
containing an aromatase knock out (ArKO) or overexpression (AROM+). Vinculin served as loading control. 
B-D: Densitometric analysis based on the Western blot in (A). Statistics were performed with paired, one-tailed 
t-tests. PKG I was significantly upregulated in AROM+ mice compared to ArKO and WT (n=5, *p<0,05, B). 
PDE5 expression was also significantly higher in AROM+ mice compared to ArKO and WT (n=5, *p<0,05, C). 
Expression of sGC showed no significant differences (D). 
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Fig.21: cGMP-dependent protein kinase I regulation in peri-glandular and vascular SMCs of ArKO, 
WT and AROM+ mice. 
A-B (ArKO): Immunostaining for PKG I (A) demonstrated its expression in cells of the vasculature (v) but 
barely around prostatic glands (g) in mice containing an aromatase knock out. Corresponding serial section to 
(A) labeled for SMA (B) localized SMCs in vessels and around prostatic glands. C-D (WT): Striking 
expression of PKG I (C) in peri-glandular SMCs (arrows) and vascular SMCs of wild type mice. 
Corresponding serial section to (C) showed SMA (D) expression in both, peri-glandular and vascular SMCs.  
E-F (AROM+): Dramatic upregulation of PKG I (E) expression in peri-glandular SMCs of mice that showed 
an aromatase overexpression. Corresponding serial section to (E) labeled for SMA (F) demonstrated 
comparable expression as seen in WT (D) and ArKO (B). Scale bars (A-F): 50 µm. 
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4.8.4   Hormonal regulation of cGMP pathway components in men 
4.8.4.1   Characterization of human prostatic interstitial cells  
Cultured human interstitial cells donated by Australian prostate cancer patients were used to 
investigate possible regulatory effects of testosterone on cGMP pathway components in 
human prostatic interstitial cells.  
 
Untreated cells were analyzed by classic immunocytochemistry using antibodies for smooth 
muscle actin, PKG I, PDE5 (Fig.22A-C) and counterstained with hematoxylin to discriminate 
their phenotypic characteristics. First of all, the expression of smooth muscle actin was found 
in all cultured human interstitial cells (Fig.22A) with almost equal intensity levels 
independent of cellular shape or dimension. This finding suggests a mostly contractile 
phenotype of the investigated interstitial cells. However, it remains unclear whether the origin 
of these cultured cells were primarily SMCs or myofibroblasts or both. 
 
 
 
Furthermore, the cGMP target protein PKG I was shown to be expressed in almost all 
cultured cells with slight differences in intensity among cells of the same population 
Fig.22: Characteristics of human prostatic 
interstitial cells.  
A-C: Immunostaining of cultured human interstitial 
cells, labeled with antibodies for SMA (A), PKG I (B) 
and PDE5 (C). Due to the remarkable expression of all 
three proteins, a contractile phenotype of these cells 
was assumed. Scale bars (A-C): 50 µm. 
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(Fig.22B). Finally, the cGMP degrading enzyme PDE5 was also found in most cultured 
interstitial cells (Fig.22C) with little exception of only a few enlarged cells. The visible 
expression of both cGMP pathway components, PKG I and PDE5 encouraged the suggested 
contractile phenotype of the investigated cultured human interstitial cells.   
   
4.8.4.2   Testosterone treatment of human prostatic interstitial cells  
In a second step, cultured human interstitial cells were treated with two different 
concentrations of dihydrotestosterone (DHT) to identify possible regulatory effects on certain 
cGMP pathway components.  
 
 
 
Fig.23: qPCR of cGMP pathway components in human prostatic interstitial cells.  
A: Significant upregulation of SMA mRNA in case of DHT treatment with a low concentration of 10 nM 
compared to the superphysiologic concentration of 15 µM DHT and vehicle control. B-C: Expression 
(relative to the housekeeping gene GAPDH) of PKG I (B) and PDE5 (C) revealed upregulation of both 
mRNAs after treatment with 10 nM DHT. D: No statistical difference regarding the expression (relative to the 
housekeeping gene GAPDH) of sGC mRNA was found after both DHT treatments. All statistical analysis 
based on t-tests (paired, one-tailed) for comparisons between individual mRNA levels.   
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In detail, cells were pretreated with either a physiological (10 nM DHT) or superphysiological 
(15 µM DHT) concentration of dihydrotestosterone. After 24 hours of incubation with DHT, 
cells were harvested in mercaptoethanol and processed for mRNA quantification via qPCR. A 
significantly increased mRNA level of smooth muscle actin was found (Fig.23A) in case of 
the cellular pretreatment with 10 nM DHT compared to 15 µM DHT and vehicle control. This 
finding might indicate the increase to a rather pure contractile phenotype of those cultured 
interstitial cells pretreated with physiological DHT concentration.  
 
This assumption was confirmed by the analysis of further mRNAs from muscle typical 
proteins, such as PKG I (cGMP target protein), PDE5 (degrades cGMP) or sGC (produces 
cGMP). Relative expression of PKG I was found significantly upregulated after pretreatment 
with the physiological concentration of 10 nM DHT (Fig.23B) compared to treatment with 15 
µM DHT. Similar to PKG I, relative expression of PDE5 revealed a significant upregulation 
(Fig.23C) in cells pretreated with the physiological DHT concentration in comparison to those 
receiving the higher dose. 
 
Surprisingly, mRNA levels of the cGMP-producing enzyme sGC showed no significant 
differences (Fig.23C) in any case of DHT pretreatment. This in turn, might suggest that sGC 
is probably not affected by changing testosterone levels. 
 
4.9   Visualization of SMC proliferation in BPH tissue 
The current knowledge, whether or not prostatic SMC proliferation is active during pathologic 
benign prostatic hyperplasia (BPH) development is still rare. For this purpose, the three-
dimensional CLARITY approach was used to check for potential SMC proliferation. Biopsies 
donated by BPH patients were investigated using a double staining protocol for smooth 
muscle actin and Ki67 together with the general nuclear marker DAPI (Fig.24A-B).  
 
A proliferation was clearly visible in interstitial SMCs of human BPH tissue samples 
(Fig.24B). Identification of these proliferative SMCs was performed by co-localization with 
the expression of smooth muscle actin as well as the shape of the cell nuclei, characterized by 
a rather oval contour of those nuclei compared to round nuclei of epithelial cells.  
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Proliferative activity was detected also in nuclei of glandular epithelial cells (Fig.24B). In 
general, human BPH biopsies regularly showed more proliferating cells within the glandular 
epithelium compared to interstitial SMCs (Fig.24A).  
 
Proliferation of peri-glandular SMCs (Fig.24C-D) was also visible in the ventral prostate of 
adult rats without enlargement disorder. In rat, immunostaining for Ki67 confirmed the 
previous impression from human BPH tissue and demonstrated an even higher amount of 
proliferative epithelial cells compared to proliferative peri-glandular SMCs.  
 
 
 
 
 
Fig.24: Proliferation of prostatic SMCs in human BPH patient and rat prostate tissue. 
A-B: CLARITY double staining from human prostate biopsies of diagnosed BPH used SMA (green), Ki67 
(red) and DAPI (blue) to visualize proliferating nuclei. Higher magnification revealed proliferation in oval-
shaped nuclei of peri-glandular SMCs (NSMC), apart from rather round-shaped nuclei of epithelial cells (NE). 
C-D: Immunostaining of prostate tissue in adult rats without enlargement disorder showed proliferating 
nuclei of both cell types, glandular epithelium and peri-glandular SMCs. Scale bars (A, C): 75 µm, scale bars 
(B, D): 25 µm. 
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5 Discussion 
 
In the present study PDE5 (degrades intracellular cGMP) was found to be expressed 
exclusively in SMCs of the vasculature and those surrounding prostatic glands and ducts. 
Within the rodent and human prostate, our three-dimensional approach (based on CLARITY) 
revealed in detail the cellular arrangement of PDE5-expressing SMCs around prostate glands. 
Inhibition of PDE5 using sildenafil resulted in significant reduction of the spontaneous 
contractility of human and rat prostate tissue by time-lapse imaging based on 
transillumination microscopy. Spontaneous contractions of prostatic SMCs were only found 
around prostate glands whereas prostatic ducts lacked any spontaneous contractions even 
though massive contractions of the whole duct could easily be induced by addition of 
noradrenaline. Testosterone deprivation due to aromatase overexpression (AROM+) in 
genetically modified mice mediated a striking upregulation of PDE5 and PKG I (target of 
cGMP action). In agreement, the aromatase knockout (ArKO) mice which lack estrogen 
production within the prostate (McPherson et al. 2001) showed the opposite effect. This 
hormone-dependent PKG I regulation was confirmed using castrated rats.  
 
5.1   SMCs of the human and rodent prostate 
The first part of this study focused on the general histologic description of smooth muscle 
cells present in mammalian prostate and continued with the cellular localization of certain 
enzymes involved in the cGMP pathway. Comparisons were made between rodents and 
humans that revealed species-dependent characteristics.  
 
Using our new adapted three-dimensional CLARITY approach, the rat prostate glands 
(respectively acini) were found tightly enclosed by SMCs with orientation in multiple 
directions causing particular overlapping as well as some empty areas. The lack of SMCs 
regularly found at the tip of prostatic acini could possibly be explained as persisting voids that 
remain from the need of space during postnatal development of the ductal and glandular 
system. Cunha and colleagues localized (1987) the formation of new branchpoints at the distal 
tip of the ductal/glandular network. Therefore, it seems useful to induce development of new 
branches in parts of the distal tips in which the formation of those branches is not impeded by 
peri-glandular SMCs. In contrast to the peri-glandular/peri-ductal SMCs of the rat prostate, 
the human prostate possesses SMCs in all parts of the prostatic stroma alternated by 
connective tissue. The reason for this histological difference between both species might be a 
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result of the different gross anatomy found in both. Compared to the compactly organized 
human prostate glands, rodent acini were found rather loosely connected via sparse 
connective tissue.  
 
However, transport of secretion might also be affected by different SMC locations. While 
bandage-like SMCs of the rodent prostate tightly encircle acini in various directions and thus 
possibly mediate a selective fluid transport by direct reduction of the acinus diameter, 
transport of secreted fluid in humans might function in a more indirect way. Due to the fact 
that SMCs were present in all parts of the human stroma, contraction of these interstitial 
SMCs may cause a reduction of the stromal tissue which in turn would drain nearby glands. 
 
Former studies by Ishihara and colleges (1978) showed proximal prostate ducts in rodents to 
be encircled by multiple layers of SMCs. It has been suggested that prostate ducts do not 
appear to secrete prostatic fluid but rather actively help to drain the acinus during ejaculation 
(Lee et al. 1990). This assumption could also be applicable for human prostate ducts and if so 
demonstrates the importance to distinguish between glands and ducts in case of investigations 
with a focus on certain drug effects or basic research.   
    
Apart from prostate glands and ducts, SMCs are also important for the regulation of the blood 
flow as these cells determine the vascular diameter. In both rat and human, SMCs were 
clearly visible in circular orientation along the prostatic vascular system using antibodies that 
bind to smooth muscle actin. Double staining with an additional antibody for calponin 
performed in the present study revealed sparse expression of calponin in SMCs of human 
blood vessels compared to smooth muscle actin, while most interstitial SMCs expressed both 
muscle markers. Calponin, a troponin-T like protein binds to actin, myosin, Ca2+-binding 
proteins and tropomyosin. Calponin inhibits the actomyosin ATPase and prevents the 
movement of actin filaments which indicates its important role in the Ca2+-dependent 
regulation of actin-myosin interaction during smooth muscle contraction. (Liu and Khalil 
2018; Kreipke and Rafols 2009; Birukov et al. 1991). Due to its expression in SMCs of the 
contractile phenotype, calponin is supposed to be a sensitive indicator for smooth muscle 
differentiation (Saboor et al. 2016; El-Mezgueldi 1996). A study in genetically modified mice 
that lack the Cnn1 gene (encoding calponin isoform 1), confirmed the importance of calponin 
for vascular development as these mice showed an impaired blood vessel maturation 
(Yamamura et al. 2007). The lack of calponin in vascular SMCs of the human prostate 
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observed in the present study might be an indication for vascular remodeling, compared to the 
rather full developed SMCs of the surrounding stroma.  
   
In contrast, peri-glandular SMCs of acini from the rat and mouse prostate express smooth 
muscle actin as well as calponin in comparable quantities. Double staining in mouse however, 
revealed few glands to share more calponin than smooth muscle actin which indicates a fully 
developed prostate. Furthermore, the general muscle cell marker smooth muscle actin was 
found to be enriched in some parts of the mouse acini which possibly demonstrate functional 
and/or anatomical differences along a single prostatic acinus, while calponin was found to be 
expressed with equal intensity in peri-glandular SMCs indicating differentiated SMCs to be 
developed equally in all parts of the mouse acinus.   
 
Innervation of acinar SMCs in the mouse prostate was visualized by staining with α-tubulin 
using our CLARITY approach. α-tubulin clearly showed the distribution of the autonomic 
nervous system around prostatic acini. To estimate especially the amount of noradrenaline-
containing nerve fibers, a double staining with antibodies for α-tubulin and the enzymes of 
catecholamine synthesis (such as tyrosine hydroxylase, aromatic L-amino acid decarboxylase 
or dopamine beta-hydroxylase) or use of the SPG (sucrose-potassium phosphate-glyoxylic 
acid) method (Gray et al. 2007; Fukuda et al. 1996) would be of interest.  
 
5.2   Localization of key proteins of the cGMP pathway  
Signaling pathways using cGMP are crucial to mediate smooth muscle relaxation beside 
many other important cell processes. PDEs are known to degrade cGMP via hydrolysis, with 
PDE5 representing a cGMP-specific member of the PDE family. Its precise histologic 
localization was therefore, one of the main aims for this study. 
In men, PDE5 was shown to be present in SMCs of the prostate glands, ducts and vasculature. 
This was clearly visible by double stainings together with smooth muscle actin not only in 
classic two dimensional DAB stainings on serial sections but especially with our three-
dimensional CLARITY approach. CLARITY broadened our understanding of the spatial 
arrangement and function of SMCs around mammalian prostate glands (Kügler et al. 2018). 
In rodents, investigations on prostatic blood vessels confirmed expression of PDE5 
(exclusively) in vascular SMCs. In contrast, PDE5 was barely localized peri-glandularly 
around acini of rat and mouse prostate. In general, visualization of the complete vasculature 
was often limited since smaller capillaries lack measurable fluorescence. This could be 
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explained by the fact that in the present study only muscle markers were investigated and 
(smaller) capillaries do not contain SMCs (Townsley 2012). In addition, a methodological 
limitation might also involve problems of antibody staining, its detection by laser- scanning 
microscopy or the computer-based three-dimensional reconstruction of our CLARITY 
protocol.  
 
Another important enzyme involved in the cGMP signaling pathway is the protein kinase 
PKG I that is known to mediate smooth muscle relaxation (Wolfertstetter et al. 2013; Francis 
et al. 2010; Schlossmann et al. 2003). Again PKG I expression was found only in SMCs 
within the prostatic vasculature and stroma of both, human and rodent prostate using classical 
immunostaining as previous studies showed before (Francis and Corbin 1994; Wolfe et al. 
1989; Lincoln 1983). This SMC localization matches former investigations in rat lungs 
describing the expression of PKG I in SMCs of the airways and of the bronchial arteries but 
not in the lung epithelium (Zhan et al. 1999).  
 
Interestingly, CLARITY-based immunostainings showed PKG I expression additionally 
around prostatic acini which might reflect a different subcellular distribution compared to 
structural proteins.   
 
5.3   Visualization of SMC function and relaxation for BPH treatment 
Smooth muscle tone can be separated into two compartments: neurogenic tone (mediated by 
the release of neurotransmitters like noradrenaline from the autonomic nervous system to 
ensure movement of the secreted fluid into the prostatic urethra during ejaculation) and 
myogenic tone (spontaneous rhythmicity of the prostatic tissue, stimulus-independent from 
the autonomic nervous system). While previous studies focusing on spontaneous contractile 
activity were performed in mostly guinea-pigs, the human prostate is only insufficiently 
described (Lee et al. 2017; Chakrabarty et al. 2015; Exintaris et al. 2009; Exintaris et al. 2006; 
Oh et al. 2003). 
 
This study visualized the spontaneous contractile activity of SMCs surrounding the rat 
prostatic acini respectively SMCs present in the stroma of the human prostate. The frequency 
of spontaneous contractility was highly comparable between both species and varied between 
0.1 to 2.3 cycles/ min. Based on time-lapse imaging, our approach provided rapid and reliable 
contraction analyses. Especially investigations of rat prostate were appropriate for this method 
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due to its translucent architecture. Since proximal ducts could easily be separated from their 
remaining glands within the distal aspect of the rat prostate, pharmacologic effects could be 
analyzed individually in isolated prostatic structures. Therefore, time-lapse imaging gave a 
much better understanding of how interstitial SMCs contract spontaneously compared to other 
experimental techniques like organ bath. Transillumination microscopy also allowed 
simultaneous determination of contractile frequencies at different sites of one individual 
gland, while organ bath recordings might only reflect a sum of several contractile parts of the 
investigated tissue. In contrast to complicated cinematographic approaches used in the past, 
today´s modern digital image analyses are readily available and easy to handle for further 
statistical procedures (Mietens et al. 2014). In addition, time-lapse imaging is found to be less 
invasive in case of tissue preparation due to the experimental set up of the organ bath which 
can cause tissue damage while holding the tissue in place by clamps and/or applying pre-
tension at the beginning of the organ bath experiment. Therefore time-lapse imaging is highly 
suitable for systematic molecular and drug analysis. However, spontaneous contractions of 
glandular SMCs probably provide a basal muscle tone, necessary for agitation of secreted 
fluid in the glandular lumen. This in turn, supports the assumption of prostatic pacemaker 
cells, generating nervous system-independent contractions which were suggested in human 
and guinea pig prostate (Nguyen et al. 2011).     
 
Surprisingly, prostatic ducts were found to lack spontaneous contractile activity. The 
physiological function of ducts seems to rather be the guidance of secreted fluid and not 
secretion itself, highlighted by the powerful response after addition of noradrenaline. 
Furthermore, prostatic ducts showed no visible response to treatment with PDE5 inhibitors 
(sildenafil). The reason for this insensitivity to sildenafil was most certainly not the lack of 
PDE5 in those structures, as PDE5 expressing SMCs were clearly localized in multiple layers 
around all investigated ducts. Therefore PDE5 action in peri-glandular SMCs possibly differs 
from those cells around prostate ducts. It could be that PDE5 in ductal musculature maintains 
a basic tension to facilitate rapid catecholamine-induced contractions during emission (Kügler 
et al. 2018).       
 
In contrast to prostatic ducts, glands of the prostate clearly showed a visible response to 
treatment with sildenafil. In both, man and rat prostate, spontaneous contractile activity was 
significantly reduced after the addition of sildenafil. For the first time, sildenafil action was 
cinematographically visualized on living prostate tissue. This indicates sildenafil treatment to 
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be only effective in glandular SMCs and not interfering with ductal SMCs. It would be of 
interest to investigate to what extent other cGMP specific PDEs, such as PDE6 or PDE9 
contribute to prostatic contractility. Systematical testing of further PDE inhibitors respectively 
a combination of different PDE inhibitors would extend our knowledge about the physiology 
and function of the ductal network in the prostate.   
 
In parallel with investigations on glandular and ductal SMCs, the musculature of the prostatic 
blood vessels was tested by time-lapse imaging regarding any visible response to treatment 
with sildenafil. Noradrenaline-induced contractions in prostatic vasculature were found to be 
abolished by incubation with sildenafil. Studies on vasoactive effects of sildenafil revealed the 
prostatic blood flow to be increased by approximately 75% which can be seen as a 
consequence of increased vascular SMC relaxation (Haaga et al. 2007). Another organ bath 
study which focused on human penile blood flow demonstrated sildenafil-induced inhibition 
of noradrenergic contractions together with an inhibition of smooth muscle contraction on 
precontracted vessels (Medina et al. 2000). All of these findings point to the assumption that 
an increased intraprostatic blood flow would probably enhance the effectiveness of medical 
treatment.    
 
5.4   Hormonal influences on the cGMP pathway 
5.4.1   Effects of hormonal changes due to prostatic postnatal development 
Besides inhibition of single cGMP pathway components, numerous components were tested 
regarding their regulation by sex hormones. Natural changes in testosterone serum levels 
occur during postnatal development and were therefore investigated first. In both men and 
rats, testosterone shows very low levels shortly after birth and increases constantly until 
adulthood (Picut et al. 2018). Due to this fact, comparative investigations on rat prostate tissue 
from two different ages (postnatal day 6 and adult) exhibited postnatal prostate to be less 
distinct and organized regarding their typical architecture of PDE5 expressing SMCs. It is a 
matter of fact that organogenesis including SMC development is linked directly or indirectly 
to androgens through specific developmental genes (Francis and Swain 2017; Marker et al. 
2003) which would explain the less distinct SMC organization of postnatal animals found in 
this study. It would be interesting to investigate fetal SMC organization around prenatal day 
17 on which testosterone level is typically increased (Chen et al. 2009; Habert and Brignaschi 
1991).  
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5.4.2   Hormone deficiency-induced regulation of the cGMP pathway in rodent prostate 
A more direct way to study the influence of sex hormones was to manipulate its production in 
vivo. The first of those studies focused on testosterone deprivation within the rat prostate 
caused by a complete testis removal (castration). Castrated animals showed upregulation of 
PKG I protein which was diminished by subsequent treatment with testosterone and therefore 
indicates a direct correlation between serum testosterone level and the amount of intracellular 
PKG I. Different to other androgen-dependent organs (e.g. penis) of the male genital tract, the 
prostate highly reacts to changing hormonal conditions. But how could this sensitivity to 
testosterone be explained? Experiments with chemical testosterone deprivation investigated in 
various organs of the rat genital tract confirmed PKG I to be androgen-regulated only in the 
prostate and suggested that in this reproductive organ, suppression of PKG I represent a 
mechanism involved in androgen-controlled balance between proliferation, differentiation and 
apoptosis (Müller et al. 2011; Sampson et al. 2007; Rommerts et al. 1988). This upregulation 
of PKG I protein could be relevant in patients undergoing androgen deprivation therapy which 
is routinely used for the treatment of prostate cancer. Parallel development of prostate cancer 
and prostatic enlargement due to BPH is widely reported. Therefore, SMC relaxation due to 
PKG I upregulation by androgen deprivation therapy could be comparable to BPH treatment 
with sildenafil that likewise reduces prostatic smooth muscle tone (Dai et al. 2016; Miah and 
Catto 2014; Alcaraz et al. 2009). In this regard, it would be interesting to test for additional 
effects of regular BPH medications like PDE5 inhibitors in combination with androgen 
deprivation therapy.     
 
Other animal models used for the investigation of possible hormone-regulated effects on the 
cGMP pathway in the prostate contained genetic modifications resulting in overexpression or 
loss of aromatase gene (AROM+, ArKO) which determines the producible amount of estrogen 
and testosterone. Histological and molecular analysis of AROM+ mice confirmed previous 
findings in rats in which reduced serum testosterone mediates upregulation of PKG I protein. 
Furthermore, these animals also showed an upregulation of PDE5 expression which 
counteracts the cGMP-induced muscle relaxation. It is currently not clear which of both 
cGMP pathway components, PKG I or PDE5 contributes more to the overall prostatic SMC 
contractility. This could be clarified in detail by time-lapse imaging or organ bath studies 
using those genetically modified animals. In this regard, it could also be tested whether the 
increased prostatic PDE5 expression reduces sildenafil effectiveness. However, the amount of 
produced cGMP seems to be non-hormonally regulated as the expression of the cGMP 
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generating enzyme sGC (β1) always equals wildtype mice. Nevertheless, it could be that 
cGMP production is still affected by sex hormones in case of a regulation by other cGMP 
generating enzymes such as GC-A and/or GC-B which needs to be investigated in further 
studies.  
 
Systematical analysis of the prostatic histology from estrogen deficiency (ArKO) mice 
revealed the peculiar finding that PKG I expression is exclusively hormone-regulated in peri-
glandular SMCs but not in vascular SMCs. This observation could be a result of different 
developmental steps during differentiation of both SMC types. Even though SMCs possess a 
mesenchymal origin, mature peri-glandular SMCs differentiate out of mesenchymal 
myofibroblasts (Shaw et al. 2008; Wong et al. 2003), while the recruitment and differentiation 
of vascular SMCs during angiogenesis starts from pericytes (Wang et al. 2015a).  In detail, 
pericytes are recruited from either the vessel wall or the surrounding mesenchymal precursor 
cells and differentiate into vascular SMCs (Yao et al. 2014; Gerhardt and Betsholtz 2003; 
Dorresteijn 1990). Different to vascularization, many important steps during prostate 
development are mediated by androgens and estrogens (Cunha 1994) which could explain the 
hormonal sensitivity of peri-glandular SMCs. Moreover, studies in rats and humans already 
demonstrated some controversial properties that separate vascular SMCs from other types of 
SMCs. Saboor and colleagues e.g. investigated in detail the histologic expression of the 
neuronal stem cell marker nestin in lungs of mice and men and found nestin solely localized 
in pulmonary vascular SMCs, but not bronchial smooth muscle cells (Saboor et al. 2016). The 
authors considered these nestin-positive vascular SMCs to be rather de-differentiated and in a 
state of changing their phenotype from contractile to synthetic (Nguyen et al. 2013; Muto et 
al. 2007). This unique characteristic of nestin-expressing vascular SMCs that contrasts the 
lack of nestin in other SMC types within the same organ was previously shown for the testis 
(Davidoff et al. 2004).    
 
However, functional studies in ArKO mice using organ bath revealed only a subtle genotype-
related increase in electrical field stimulation- and noradrenaline-induced contractility of the 
prostate (Gray et al. 2007). These findings together with the massive downregulation of PKG 
I in peri-glandular SMCs within the prostate presented in the present study suggest that 
prostatic contractility in these mice needs to be ensured by pathways different from PKG I 
such as the MAPK/ERK pathway (Pfeifer et al. 2014; Kinkade et al. 2008). It might be 
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interesting to investigate whether spontaneous contractility of the ArKO mice would remain 
unchanged. 
 
5.4.3   Testosterone deficiency-induced regulation of the cGMP pathway in humans  
In order to validate our previous findings of the rodent ventral prostate, cell culture 
experiments in human prostatic interstitial cells served as a reliable model to investigate 
possible hormone-induced effects on the cGMP pathway. SMC characteristics of these cells 
were confirmed by the expression of smooth muscle actin as well as PDE5 and PKG I. Both 
proteins are typically found in cells with contractile phenotype even so some of the larger 
investigated cells lacked PDE5 expression which could theoretically indicate a transformation 
into (myo-) fibroblasts of those cells. Another study on cultured human prostatic stromal cells 
investigated fibroblast-to-myofibroblast trans-differentiation in more detail, which is 
considered to be the major mechanism in BPH (Zenzmaier et al. 2012; Tuxhorn et al. 2002a). 
Addition of TGFβ1 mediated trans-differentiation of these stromal cells to a rather contractile 
phenotype, being indicated by an increase of smooth muscle actin as seen in Western blot and 
qPCR. The proportion of trans-differentiated cells was diminished by pre-incubation with the 
PDE5 inhibitor tadalafil but not by pre-incubation with the PKG inhibitor KT2358 
(Zenzmaier et al. 2010). Furthermore, it could be shown that PDE5 inhibition by tadalafil 
reduced proliferation of prostate-derived fibroblasts. It would be interesting to validate these 
findings using the human prostatic interstitial cells of the present study.  
 
Experiments on human prostatic interstitial cells in the present study however, focused on the 
influence of testosterone on important cGMP pathway components using qPCR. In this 
regard, testosterone-induced downregulation of smooth muscle actin, PDE5 and PKG I were 
shown on a mRNA level and confirmed protein data from Western blot experiments of 
castrated rats previously discussed in this study (see 5.4.2). The incubation time of 24 hours 
with testosterone provided enough time for the cells to mediate protein synthesis by gene 
transcription and translation. In theory, it is presumed that testosterone action, likewise to 
other steroid hormones is able to freely cross the plasma membrane to enter the cytoplasm and 
bind to the androgen receptor (Hiipakka and Liao 1998; Beato 1989). This in turn, leads to an 
activation of the bound androgen receptor which acts as transcription factor for DNA response 
elements in the gene promoters of the target protein (Costello and Franklin 2002) such as 
PDE5 or PKG I. Finally, activation of transcription and subsequent protein synthesis would 
lead to the observed upregulation of PDE5 and PKG I protein within the prostatic SMCs 
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(Heinlein and Chang 2002). Genomic action is assumed when latency between hormone 
exposure and the observed response is no shorter than the time it takes to trigger gene 
transcription followed by protein synthesis (Foradori et al. 2008). Duration for gene 
transcription is estimated for several hours after hormone exposure, followed by at least 7.5 
min of transcription with some additional time for mRNA translation into proteins, their 
posttranslational modification and final accumulation (Cato et al. 2002; Cato et al. 1988; 
Groner et al. 1983). Apart from that, non-genomic pathways may also play a role in the 
realization of hormone-induced upregulation of cGMP pathway components. In contrast to 
genomic actions, hormone-induced non-genomic pathways are assumed to take only seconds 
to minutes to initiate measurable responses (Leach et al. 2014; Pi et al. 2010). Numerous 
studies describing interactions between such non-genomic pathways and intracellular 
signaling molecules such as mitogen-activated protein kinases (ERK1, ERK2) or a cross-talk 
with other factors (e.g. glucocorticoid receptor) were published (Oliver et al. 2013; 
Bonaccorsi et al. 2004; Castoria et al. 1999; Göttlicher et al. 1998).  
 
Apart from PDE5 and PKG I, the cGMP-generating enzyme sGC was analyzed in addition. 
More precisely, the catalytic active sGC exists as heterodimer always containing one α and 
one β subunit (Denninger and Marletta 1999). Two isoforms of sGC (α1β1 and α2β1) are 
described to show catalytic enzyme activity (Korkmaz et al. 2018). The α1/β1 heterodimer is 
assumed to be the most abundant form (Mergia et al. 2003; Garbers 1992). sGC uses NO as 
its substrate to bind to the heme in the β1 subunit and induces conversion of GTP into cGMP 
(Krumenacker et al. 2004). As already discussed in case of aromatase mouse models (see 
5.4.2), sGC expression seems to be not influenced by testosterone treatment, when targeting 
its β1 subunit by Western blot analysis. Studies on androgen-sensitive prostatic cancer cells 
(LNCaP) also demonstrated no testosterone regulation of the weakly expressed β1 subunit on a 
protein and mRNA level (Cai et al. 2007). This study showed only α1 subunit to be regulated 
by testosterone. It would be interesting to repeat these experiments using the human prostatic 
interstitial cells from the present study with special focus on the α1 subunit of sGC. In 
contrast, Müller et al. (2011) found sGC expression remarkably increased in Western blot 
analysis using an antibody for the β1 subunit of sGC after Leydig cell depletion by injection of 
the compound ethane dimethane sulfonate (EDS). However, differences in expression 
between α1 and β1 subunits of sGC were also shown in studies of breast cancer cells which 
might have importance in the development of hormone-dependent cancers (Mónica and 
Antunes 2018; Postovit et al. 2002).  
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5.5   SMC proliferation in BPH tissue 
BPH (benign prostatic hyperplasia) is described as a net increase in cell number within the 
prostatic interstitial stroma (Wu et al. 2008; Djavan et al. 2002). The histological diagnosis of 
BPH is characterized by unregulated proliferation of connective tissue, SMCs and glandular 
epithelium within the transition zone and periurethral aspect of the prostate (Patel and Parsons 
2014). However, the pathophysiology underlying the development of BPH is highly complex 
and insufficiently understood (Shi et al. 2018).  
 
The present study showed visible proliferation in interstitial SMCs of human BPH tissue 
samples from the transition zone after transurethral resection of the prostate. Proliferative 
activity was also detected in nuclei of the glandular epithelium in the rat and human prostate 
with even higher prevalence of this cell type.  The cellular pathology of BPH includes varying 
proportions of epithelium, fibrous connective tissue as well as SMCs and is most commonly 
found as adenomyofibromatous subtype while pathologists usually do not subclassify BPH 
histologically because of the wide variation in composition (Kirby 2005).  
 
Moreover, an increased hyperplastic growth of prostatic SMCs contributes to urethral 
obstruction and voiding symptoms in BPH (Shi et al. 2018). In this regard, it is assumed that 
different proliferative potential of stromal cells between transition zone and adjoining regions 
of the prostate is crucial for the development of BPH (Foster 2000).   
 
Taken together, these findings demonstrate the limitation of our knowledge about the 
underlying mechanisms of BPH development.  Further investigations are therefore absolutely 
essential, in which CLARITY could help to extend our knowledge.   
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6 Summary 
 
Prostatic enlargement due to benign prostatic hyperplasia (BPH) and/or prostate cancer are 
ubiquitous in aging men. While prostate cancer represents the sixth leading cause for cancer-
related death worldwide, BPH is known to result in urinary retention and recurrent infections 
which adversely influences the quality of life among older men. Although inhibitors of the 
cGMP-hydrolyzing enzyme phospodiesterase 5 (PDE5) are now regularly used for the 
treatment of BPH, detailed information about their cellular localization and function within 
the prostate is missing.  
 
In prostate tissue of mouse, rat and man, PDE5 was shown to be highly expressed in 
interstitial and vascular smooth muscle cells (SMCs) but not in epithelial cells of the gland. 
The newly established CLARITY approach helped to improve our understanding of the 
prostatic architecture on a three-dimensional level and allowed highly precise reconstructions 
of the arrangement of PDE5-expressing SMCs. Moreover, this method demonstrated that the 
interstitial periglandular SMCs in rat prostate are arranged tighter around the glands than in 
the human prostate. Spontaneous contractions of these SMCs were visualized by the use of 
time lapse-imaging in both, rodents and men. Addition of the PDE5 inhibitor sildenafil 
resulted in a significant reduction of the crontractile frequency in both tissues. In rat prostate, 
spontaneous contractility was only observed in terminal prostatic glands but not in proximal 
ducts. 
 
The regulatory role of sex hormones on the cGMP pathway within prostatic SMCs was 
another important aspect of this study. In rat, androgen deprivation was induced via castration 
which increased the expression of prostatic cGMP pathway components considerably. Using 
estrogen-deficient aromatase knockout (ArKO) and -overexpressing (AROM+) mice, we 
found only glandular but not vascular smooth muscle cells affected by changes of hormone 
levels. These findings were consistent even in the human prostate by culturing of isolated 
prostatic interstitial cells as mRNA expression of cGMP pathway components increased with 
decreased concentrations of testosterone pretreatment.    
 
Data, showing relevant PDE5 effects and their androgen-dependent regulation might be 
helpful to clarify whether PDE5 inhibitors as new therapeutics aspects for BPH are only 
effective in case of reduced testosterone levels. 
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7 Zusammenfassung 
 
Die Vergrößerung der Prostata in Folge einer benignen Prostatahyperplasie (BPH) oder 
Prostatakarzinoms ist bei Männern im hohen Alter weit verbreitet. Während 
Prostatakarzinome eine der häufigsten Ursachen für tödlich verlaufende Krebserkrankungen 
darstellen, beeinträchtigt BPH die Lebensqualität älterer Männer erheblich durch 
Folgeschäden, wie Harnverhalt und wiederkehrende Infektionen. Obwohl Inhibitoren des 
cGMP hydrolysierenden Enzyms Phosphodiesterase5 (PDE5) nun auch routinemäßig zur 
Behandlung von BPH eingesetzt werden, fehlen noch immer detaillerte Informationen über 
Lokalisation und Funktion in der Prostata. 
 
In Gewebeproben der Prostata von Mäusen, Ratten und humanen Spendern konnte die PDE5- 
Expression in glatten Muskelzellen des Interstitiums und der Gefäße nachgewiesen werden. 
Hierbei exprimierten die Epithelzellen der Prostatadrüsen jedoch kein PDE5. Ein neu 
entwickeltes CLARITY-Protokoll half dabei unser Verständnis der Prostataarchitektur um die 
dritte Dimension zu erweitern und erlaubte eine exakte Rekonstruktionen der räumlichen 
Anordnung PDE5-exprimierender glatter Muskelzellen. Zudem konnte mit dieser Methodik 
anschaulich gezeigt werden, dass in der Rattenprostata periglanduläre glatte Muskelzellen eng 
anliegender und kompakter um die einzelnen Drüsen angeordnet sind, im Vergleich zur 
humanen Prostata.  Spontan auftretende Kontraktionen dieser glatten Muskelzellen konnten 
mittels time-lapse imaging sichtbar gemacht werden. Dabei führte die Zugabe des PDE5-
Inhibitors Sildenafil zu einer signifikant reduzierten Kontraktionsfrequenz in Gewebestücken 
aus beiden Spezies. Bei der Ratte konnte darüberhinaus gezeigt werden, dass die 
Spontankontraktionen nur die Drüsenendstücke , aber nicht die Ausführungsgänge betrafen. 
 
Die Möglichkeiten zur Regulation des cGMP-Signalwegs durch Geschlechtshormone wurde 
als ein weiterer wichtiger Punkt näher untersucht. In der Prostata der Ratten wurde die 
Androgenzufuhr durch Kastration unterbunden, was zu einem deutlichen Anstieg von cGMP-
Signalwegskomponenten führte. Unter Verwendung von Mausmodellen, welche einen 
Aromatase-Knockout (ArKO) bzw. deren -Überexpression (AROM+) aufwiesen, konnte ein 
Einfluss durch unterschiedliche Hormonlevel auf glatte Muskelzellen gezeigt werden. Dies 
betraf auschließlich glatte Muskelzellen der Drüsen und hatte keinerlei Effekt auf 
Gefäßmuskelzellen. Diese Ergebnisse decken sich mit Versuchen mit isolierten interstitiellen 
Zellen menschlicher Prostatae. Hier konnte ein Anstieg der Expression von cGMP-
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Signalwegskomponenten durch Inkubation mit sinkenden Testosteronkonzentrationen gezeigt 
werden.      
 
Diese Daten verdeutlichen die Androgen abhängige Regulierung von cGMP-
Signalwegskomponenten in glatten Muskelzellen der Prostata, welche dabei helfen könnte, 
die Frage zu klären, ob PDE5-Inhibitoren als neue Therapeutika für BPH nur unter niedrigen 
Testosteron-Level wirksam sind.   
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